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Exosomes (EXOs) are nanovesicles of diameter ranging between 50 
to 140 nm, distinguished from other cell-derived vesicles by their 
origin, size, morphology and composition. Their stimulatory or 
inhibitory signaling activities are mediated by their content (mRNAs, 
microRNAs and proteins) that can be transferred from the cells of 
origin to recipient cells, influencing the surrounding 
microenvironment besides cell behavior. In this study we 
investigated EXO-mediated communications in two cancer models, 
melanoma and Ewing’s sarcoma.  
In view of our previous results demonstrating miR-221&222 as key 
factors for melanoma development and dissemination, we 
demonstrated that the EXO-mediated horizontal transfer of miR-222 
was competent to deliver miR-222-associated properties increasing 
tumor malignancy.  
Melanoma-purified vesicles were characterized and investigated for 
the functionality of miR-222 in EXO-mediated tumorigenesis. Our 
data showed that EXOs secreted by miR-222-overexpressing cells 
induced a protumorigenic program in target cells, mainly through the 
upmodulation of the PI3K/AKT pathway. The reverse effects were 
obtained with EXOs recovered after inhibition of endogenous miR-
221 and miR-222 by antagomir transfections. The possible 
differential significance of PI3K/AKT blockade in miR-222-
transduced vs control cells was assessed by using BKM120, a pan 
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inhibitor of PI3K. Results showed the capability of miR-222 
overexpression to overcome BKM120-dependent effects.  
We then demonstrated the role of Ewing’s sarcoma-derived EXOs as 
mediators of signals involved in cancer growth, metastases and 
differentiation. Ewing’s sarcoma (EWS) is an aggressive childhood 
bone tumor characterized in the majority of cases by the presence of 
the fusion oncoprotein EWS-FLI1 and by high expression of the 
membrane glycoprotein CD99. These features, which are the 
necessary conditions for the pathogenesis of EWS, mediate tumor 
progression and maintain the cells in a dedifferentiated state. We 
evaluated the ability of EXOs, expressing or not CD99, to modulate 
the phenotype of EWS cells. We observed that the delivery of EXOs 
devoid of CD99 was sufficient to induce neural differentiation in 
EWS recipient cells through the inhibition of Notch-NF-kB signaling 
mediated by miR-34a overexpression.  
All together these observations would provide a significant step 
toward new biomarker discovery and innovative therapeutic options. 
These data on one side support miR-222 responsibility in the 
exosome-associated melanoma properties, on the other the role of 
CD99-shRNA/miR-34a-derived EXOs to induce differentiation in 
EWS, thus further indicating microRNAs as potential diagnostic, 
prognostic and eventually therapeutic biomarkers. 
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1. INTRODUCTION
1.1 Intercellular communication 
Intercellular communication is a complex process responsible for 
maintaining normal tissue homeostasis. Cells dedicate a considerable 
amount of energy and regulatory mechanisms to ensure cell-cell 
communication, as this biological process is an important aspect of 
the machinery underlying their survival, behavior and fate. Cell 
communication is vital not only to maintain the integrity and proper 
organ and tissue functions (Nakahama K., 2010; Brooke MA., 2012; 
Bruzzone R., 2006; Chanson M., 2010; Bosco D., 2011), but also 
because their roles need to be coordinated, quantitatively fine-tuned 
and/or limited in space and time. Furthermore cells make use of 
communication to minimize the energetic and signaling burden, 
whereas a single minimal signal could be amplified and propagated, 
as is for instance the case of gap junction-mediated transfer of pro-
apoptotic signals (Decrock E., 2009; Krysko DV., 2005; Vinken M., 
2006). Many types of intercellular communication have been studied, 
as direct cell-cell interactions, released growth factors and cytokines 
and the connecting functions of a variety of extracellular membrane 
vesicles, including exosomes, capable of carry and transfer their 
cargos to proximal and distant cells. Studies on these small 
transporters have revealed a significant potential for using 
microvesicles in cancer therapy. 
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1.2 Extracellular vesicles. 
An assorted group of vesicles is released from the cell surface and 
they are used as intercellular vehicles for information exchanges, 
even over long distance (Corrado C., 2013). These membranous 
vesicles, produced and released by almost every cell type, are 
generally termed extracellular vesicles (EVs). According to strict 
criteria they can be divided into three main classes: exosomes 
(EXOs), microvesicles or ectosomes, apoptotic bodies. While 
apoptotic bodies are easily distinguished based on size, origin and 
surface markers, there is some difficulty in the distinction between 
EXOs and microvesicles. Both are membrane bound vesicles, but 
diverge based on their process of biogenesis and biophysical 
properties (Colombo M., 2014). In contrast to EXOs, microvesicles 
are produced directly through the outward budding and fission of 
membrane vesicles from the plasma membrane and their surface 
markers largely depend on the composition of the membrane of 
origin. In addition, microvesicles represent a larger and more 
heterogeneous population of extracellular vesicles, ranging from 50 
to 1000 nm in diameter (Table 1). 
EXOs are small vesicles of endocytic origin (40-140 nm in diameter) 
distinguished from other cell-derived vesicles by their origin, size, 
morphology and composition, but mainly because they are released 
into the extracellular environment through fusion of multivesicular 
bodies (MVB) with the plasma membrane (Melo SA., 2014). EXOs 
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are characterized by the enrichment of specific proteins and lipids 
(i.e. cholesterol, sphingomyelin, ceramide). In addition, due to their 
endosomal origin, all EXOs contain membrane transport and fusion 
proteins (RAB family GTPases, Annexins, flotillin), tetraspanins 
(CD9, CD63, CD81, CD82), heat shock proteins (HSP70, HSP90), 
proteins involved in multivesicular body biogenesis (Alix, TSG101), 
ESCRT (an endosomal sorting complex required for transport) 
proteins, lipid related proteins and phospholipases, as well as 
cytoplasmic enzymes (e.g., GAPDH, peroxidases, and pyruvate 
kinases). Many of these proteins are currently used as exosomal 
markers (e.g. alix, flotillin, TSG101, RAB5B, CD63, CD81) to 
facilitate their specific identification (Fig.1). 
Table 1. Characteristics of vesicular bodies 
















Figure 1. Schematic representation of the molecular 
composition of exosomes (EXOs). All EXOs contain a 
cellular stew of smaller components including proteins, 
messenger RNA (mRNA) and microRNAs (miRs). 
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1.3 Exosome biogenesis. 
A general model on EXOs biogenesis has been proposed (Saleem 
SN., 2015). EXOs are formed in endosomal compartments, where 
they are called multivesicular endosomes, which contain internal 
vesicles able to package and store molecules in membrane bound 
structures. Endosomes are generally considered to function as an 
intermediate compartment between the plasma membrane, where 
endocytosis of extracellular molecules takes place, and 
compartments as lysosomes, where these molecules are released and 
degraded (Fig.2).
Figure 2. Schematic biogenesis of intraluminal vesicles 
(ILVs) and release of EXOs.  
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About 25 years ago, it was reported that in reticulocytes, undergoing 
maturation into red blood cells, multivesicular late endosomes could 
fuse back with the plasma membrane, instead that with lysosomes, 
and release their contents, including numerous small vesicles, 
extracellularly. Little is known on the mechanisms of selecting the 
content of EXOs, but it is believed to be highly regulated by the 
group of proteins involved in their biogenesis (ESCRT and non 
ESRCT complexes)(Bobrie A., 2011; Thery C., 2002). These 
complexes appear to determine the relative abundance of genetic 
information that will be packaged and transported within EXOs. The 
selection of proteins packaged into EXOs is affected by the status of 
the donor cell and the subcellular compartment of origin (Keller S., 
2006). The ESRCT complex and an ESRCT-independent mechanism 
largely dependent on the protein CD63 have been shown to sort 
proteins into EXOs suggesting that EXO packaging is regulated at 
multiple levels (Denzer K., 2000; van Niel G., 2006). The 
mechanism of sorting nucleic acids, including DNA, RNA, mRNA 
and miRs, into EXOs remains unclear. Several studies have found a 
significant increase in the production of extra-cellular vesicles, 
including EXOs, in disease states compared to non-disease states 
(Noerholm M., 2012). EXOs are implicated in the propagation and 
spread of neurodegenerative diseases such as Alzheimer’s disease 
through delivery of β-amyloid precursors to distant parts of the brain 
leading to pathological amyloid deposition (Rajendran L., 2006). 
EXOs secretion from eosinophils has been found to be increased in 
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asthmatic patients and induces enhanced proliferation and 
chemotaxis of undifferentiated macrophages in the lungs during 
acute asthmatic inflammatory conditions (Kulshreshtha A., 2013; 
Mazzeo C., 2015). In cancer, EXOs have been found to play a 
significant role. Melanoma-derived EXOs promote metastasis, EXOs 
derived from fibroblasts encourage migration of breast cancer cells 
and in general EXOs derived from cancer cells have a pro-
tumorigenic role associated with the transfer of mRNA and 
proangiogenic proteins (Peinado H., 2012; Luga V., 2012). EXOs 
derived from cancer cells can also contribute to horizontal transfer of 
oncogenes, such as EGFRvIII (Al-Nedawi K., 2008). One of the 
most interesting aspects of EXOs involvement in cancer is their 
ability to transfer microRNAs  (miRs) to recipient cells. 
Secreted vesicles known as exosomes were first discovered nearly 30 
years ago but they were originally thought to be just garbage bags, 
allowing cells to get rid of the unnecessary proteins. Over the past 
few years, however, evidence has begun to accumulate that the 
vesicles are like signaling payloads containing cell-specific 
collections of proteins, lipids, and nucleic acids (DNA, mRNA, 
miRs) (Thery C., 2011). Therefore, the most important role of these 
vesicles is their capacity to mediate communication between cells in 
diverse locations of the body. Within this conceptual framework, it 
has been convincingly demonstrated that EXOs are secreted by all 
types of cells in culture, comprising B and T cells (Zech D., 2012), 
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dendritic cells (Thery C., 1999), mast cells (Carroll Portillo A., 
2012), mesenchymal stem cells (Lai R.C., 2010), epithelial cells 
(Mallego lJ., 2007; Kapsogeorgou E.K., 2005), astrocytes (Wang G., 
2012), endothelial cells (Boettger T., 2012) and cancer cells of 
almost all histotypes (Ristorcelli E., 2008; Clayton A., 2008; Peinado 
H., 2012; Taverna S., 2012). They are found in abundance in body 
fluids including blood, saliva, urine and breast milk. The molecular 
structure of these vesicles may be diverse, as their characteristics and 
molecular cargo depend on the type and origin of the donor cells and 
their current state –for example, transformed, differentiated, 
stimulated, stressed. Johnstone and coauthors (Johnstone RM., 1987) 
were the first to isolate these nanovesicles showing that they retained 
multiple active enzymes. 
EXOs secreted by tumor cells were shown to transfer oncogenic 
properties via horizontal propagation of mRNAs, miRs and proteins. 
More important, upon their release in the extracellular environment, 
EXOs are utilized by tumors for both local and distant cellular 
communications, as these nanoparticles are able to transfer their 
cargo into the acceptor cells in autocrine and paracrine fashions 
(Squadrtito ML., 2014) (Fig.3). During the development and 
progression of cancer, the cellular composition of the tumor 
microenvironment is influenced by the activity of the tumor cells  
which recruit and educate host stromal cells into tumor supportive 
cells that actively participate in tumor progression. A way used by 
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tumor cells to communicate and alter the microenvironment is the 
constitutive release of EXOs. Recent studies have shown that EXOs 
produced by tumor cells can interact with target cells by a number of 
mechanisms, including i) direct stimulation of the target by surface-
expressed ligands; ii) receptor transfer between the tumor cell and 
the target; iii) horizontal transfer of genetic information to the target; 
iv) direct stimulation of the target cell by endocytic expressed
surface receptors  (Camussi G., 2010). Growing evidence supports 
the view that tumors constitutively shed EXOs with pleiotropic 
immunosuppressive effects that are protective and supportive of the 
tumor with effects that range from regulation of tumor growth, to 








Figure 3. EXO-mediated intercellular 
communication. Secreted EXOs can travel 
across the extracellular milieu interacting with 
target cells via their surface molecules (a), 
fusion with the plasma membranes (b) or 
internalization by phagocytosis (c). Release of 
their luminal contents can alter gene expression 
and cell signaling in recipient cells. 
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1.4 Role of exosomes in tumorigenesis. 
Tumors have many ways for manipulating their environment and 
escaping the immune system and EXOs just represent one of them. 
Indeed tumor-derived EXOs have been shown to assist tumors either 
creating a tumor friendly environment or impairing the immune 
response, thereby allowing them to escape detection by the immune 
system. Even so, tumor-derived EXOs have been demonstrated not 
only to exert protumorigenic effects, but also anti-tumorigenic ones, 
thus making them good candidates for cancer therapy too. 
1.5 Exosome-mediated effects on tumor microenvironment. 
EXOs secreted by cancer cells may facilitate metastasis through their 
direct role in invasion and through a number of cargo related effects 
that promote metastasis, transformation, and pre-metastatic niche 
formation. Examples are EXOs from metastatic melanoma which can 
educate and mobilize bone marrow progenitors leading to pro-
vasculogenic and metastatic phenotypes (Peinado H., 2012), as well 
as EXOs that can enhance cancer cell motility inducing a conversion 
of stromal fibroblasts into more invasive CAFs cells or promoting 
angiogenesis (Shimoda M., 2014; Hu GW., 2015). Accordingly, 
cancer EXOs have been shown to deliver functional molecular 
complexes capable of promoting both EMT (such as HIF-1α) and 
MET (such as miR-200), the latter miRs being reported to be 
transferred from highly metastatic human breast cancer cells in 
recipient mice promoting metastasis of the xenografts (Le M.T., 
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2014). It is interesting to note that EXOs produced by tumor-
associated stroma cells are also functional to malignancy as they are 
able to shuttle their specific cargos into adjacent cells, as 
demonstrated for breast cancer where they stimulated invasiveness 
and metastasis (Luga V., 2012). 
 
1.6 Pro- or anti-immuno-mediated effects of tumor-derived 
exosomes.  
A number of studies also showed the capability of tumor EXOs to 
modulate the immune system. Clayton et al. showed that tumor 
EXOs, expressing natural-killer group 2, member D (NKG2DLs), 
can downregulate the NKG2D-surface expression thus impairing the 
cytotoxic function of CD8+ T cells (Clayton A., 2008). Also the role 
of NKG2DL-carrying tumor EXOs has been associated with tumor 
immune escape (Hedlund M., 2011;  Ashiru O., 2010). In addition, 
tumor EXOs can also contribute to tumor immune escape by skewing 
IL-2 responsiveness, thus driving the immune responses away from 
cytotoxic T cells, instead favoring regulatory T cells (Clayton A., 
2007).  
Conversely other studies have established that tumor-derived EXOs 
do not suppress the immune system, but rather activate it. Studies 
have shown that tumor EXOs from both cell lines and malignant 
effusions from cancer patients have high levels of MHC class I, heat-
shock proteins and carry tumor specific antigens such as Mart-
1/Melan-A and gp100. Tumor derived EXOs have also been shown 
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to transfer tumor-specific antigen to dendritic cells, subsequently 
activating tumor-specific cytotoxic T cell reactivity in vitro. These 
EXOs were also demonstrated to exhibit anti-tumor effects against 
established tumors by inducing T cell mediated anti-tumor immunity 
in vivo (Wolfers J., 2001; Andre F., 2002). 
1.7 Role of exosomal RNA in cell-to-cell communication. 
EXOs have many different functions, which depend on both their 
cellular origin as well as the current state of that cell, as it influences 
the cargo of the released EXOs. However, these functions have 
primarily been associated with the exosomal proteins. The novel 
finding that EXOs contain RNA (Valadi H., 2007) has prompted 
many researchers to address the biological role of exosomal RNA, 
which further increases the complexity of the understanding of cell-
to-cell communication (Fig. 4). 
Valadi et al.  did not only demonstrate the presence of RNA in 
EXOs, but also that this RNA could be transferred to recipient cells. 
To demonstrate RNA transfer from EXO to cell, RNAs were labelled 
(i.e. with radioactive uridine) and their presence evaluated into 
recipient cells following co-culture with EXOs. Since EXOs 
themselves do not contain the complete machinery to produce 
proteins, the functionality of the RNA content was shown by using in 
vitro translation assays, mixing mouse cell-derived EXOs with 
human mast cells, and looking for newly produced murine proteins in 
the human cells. The fact that exosomal mRNA can affect the protein 
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production of recipient cells and the known capability of each miR to 
interfere with hundreds of mRNAs suggests a significant biological 






Figure 4. Sorting of cargo into EXOs. a) Schematic representation 
of miR trasport by EXO b) Sequence motifs present in certain 
miRNAs may guide their incorporation into EXOs, whereas some 
enzymes or other proteins may control sorting of exosomal miRs in a 






1.9 Biogenesis and action. 
MicroRNAs (miRs) are small endogenous noncoding RNAs, single-
stranded involved in the fine regulation of gene expression, mostly at 
post-transcriptional level. These small non coding RNAs have 
revealed a great potential as early diagnostic markers being highly 
stable and able to discriminate different subtypes of cancer (Bartels 
Cl., 2009). They were firstly discovered in 1993 by Ambros and 
colleagues when they identified a small RNA which exerted 
regulatory functions on a specific mRNA resulting in suppression of 
its action (Lee R., 1993). This small RNA was subsequently 
discovered to be a member of an abundant family of tiny regulatory 
RNAs called miRs. The importance of miRs as regulatory molecules 
has become increasingly obvious as more miRs are discovered and 
their regulatory targets are elucidated. Functional studies have shown 
miRs to participate in almost every cellular process including 
apoptosis, proliferation and differentiation (Almeida M., 2011). In 
fact, single miR may regulate multiple target genes acting as a master 
control of gene expression (Wu W., 2011). Although miRs constitute 
only 1-3% of the human genome, it is suggested that they regulate up 
to 30% of human genes (Carthew R., 2009). Since their discovery, 
over 2000 miRs have been identified in humans and this number 
continues to rise (Nugent M; 2012). In most cases, they act by 
binding, with greater or lesser complementarity, to the region 
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3'untranslated (3'-UTR) of the target messenger RNA, inhibiting the 
expression by degradation or translational block, in association with 
a large ribonucleoprotein complex (RISC). MiRs biogenesis occurs 
in three main phases. The first phase involves transcription of 
primary transcripts: RNA polymerase II or III transcribes large 
primary miRs (pri-miRs) in the nucleus. Pri-miRs are several 
hundred or thousand nucleotides in length and contain at least one 
miR stem loop (Rodriguez A., 2004). Then the action of the RNase 
III enzyme –Drosha-, combined with the microprocessor complex 
subunit -DGCR8-, cleaves the pri-miRs into precursor miR (pre-
miRs) of around 70-110 nucleotides (Bhattacharyya M., 2012). 
Critically, they contain a hairpin structure required for their transport 
to the cytoplasm from the nucleus, mediated by Exportin-5 which is 
the second phase of biogenesis (Murchison E., 2008). The third 
phase of biogenesis occurs in the cytoplasm and results in formation 
of mature miRs. Once in the cytoplasm the hairpin structure can be 
cropped by the RNAase III enzyme Dicer, to produce a double-
stranded structure consisting of the miR and its complement. This 
multi-step process culminates in the mature miR strand being 
incorporated into a miR associated RNA-induced silencing complex 
(miRISC). MiRISC interacts with target mRNA to exert functional 
effects (Fig. 5) (Lowery AJ., 2008; McDermott A., 2011).  
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MiRs exert their function on target mRNAs through two 
mechanisms, degradation of a selected mRNA or silencing of protein 
translation. If the target mRNA and miRISC have perfectly matched 
Figure 5. MiR biogenesis. MiR genes are transcribed into 
primary miRs (pri-miR), and processed by the Drosha complex to 
form precursor pre-miRs, which are exported into the cytoplasm 
by the exportin 5 complex. The pre-miRNAs undergo digestion 
by the Dicer complex to become mature miRs.  
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base pairing, the mRNA is cleaved and degraded by activation of an 
RNA mediated interference pathway. More commonly, miRs exert 
their effect by repressing protein translation which occurs when they 
imperfectly bind to partially complementary sequences in the 3’ UTR 
or 5’ UTR of target mRNAs (Jackson R., 2007). Each miR may exert 
these effects on several mRNAs resulting in their silencing or 
degradation. 
From a functional point of view it has been shown that most, if not 
all, miRs are capable of recognizing more than one target mRNA, 
and that each target mRNA can in turn be regulated by several miRs 
(Ke X.S., 2003). These data make possible to consider the individual 
miR as small control elements within complex regulatory pathways, 
and the basis for many important functions, including cell cycle 
regulation, cell proliferation, differentiation and apoptosis, to 
processes that affect the entire body, such as embryonic 
development, immune response and many others. Studies have also 
demonstrated the fundamental role of miRs in the self-renewal and 
differentiation of stem cells (Li C., 2009). Recently, data have 
emerged showing miRs as key regulators of metabolism, such as 
miR-33a and -33b that have a role in the metabolism of cholesterol 
and lipid, or miR-34 implicated in lipid homeostasis in the liver 
(Rottiers V., 2012). As miRs, exert fundamental physiological 
functions, their altered expression is obviously involved in several 
diseases, including cancer.  
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1.10 MicroRNA and cancer. 
The first study suggesting miRs involvement in cancer was published 
just over a decade ago. Croce et al. demonstrated the association of 
the loss of miR-15a and miR-16-1 with a deletion at chromosome 
13q14, a region frequently deleted in human B-Cell Chronic 
Lymphocytic Leukemia. A large number of miRs were subsequently 
found to be dysregulated in a broad spectrum of cancers. Cancer-
specific expression patterns of miRs reflect mechanisms of cellular 
transformation and can provide a new insight into carcinogenesis. Of 
course there were many other cases, one of the most famous is that of 
the family of the miRs let-7 (key stages in the regulation of C. 
Elegans development), composed of 12 counterparts organized into 
eight clusters. A downregulation of these miRs is associated with a 
poor diagnosis of lung cancer (Takamizawa J., 2004; Yanaihara N., 
2006), since the reduction of their transcripts leads to an increase in 
the protein levels of two of their targets, KRAS and NRAS, potential 
highly oncogenic proteins, which are mutated in 15-30% of tumors 
(Johnsonn S.M., 2005). An opposite situation occurs for the miR-17-
92 cluster (miR-17, miR-18, miR-19a, miR-19b and miR-92) located 
in a region of chromosome 13 (13q31.3), which is amplified in 
several types of cancer (such as lymphomas and lung tumors) (Ota 
A., 2004; Hayashita Y., 2005). The main focus of miRs research in 
cancer has been in the identification of their up- or down-regulated 
levels in the tissues, circulation or biological fluids of cancer 
patients. Several previous studies have profiled exosomal miRs in 
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different samples and some exosomal miRs can be used to aid in 
clinical diagnosis. For example, a set of exosomal miRs, including 
let-7a, miR-1229, miR-1246, miR-150, miR-21, miR-223, and miR-
23a represent a diagnostic biomarker for colorectal cancer  (Ogata-
Kawata H., 2014) and miR-1290 and miR-375 for castration-resistant 
prostate cancer (Huang X., 2015). The therapeutic use of miRs has 
already been established for miR-26 (Kota J., 2009) and miR-34 
(Wiggins J.F., 2010; Kasinski A.L., 2012), the latter representing one 
of the most documented tumor suppression-associated miRs, being 
transcriptionally induced by the genome guardian p53, when in its 
wild-type form. Pre-clinical work by MIRNA THERAPEUTICS has 
demonstrated potent anti-tumor effects by introducing miR-34a 
mimics into a variety of mice cancer models (Liu C., 2011; Trang P., 
2011) and a clinical trial has been already planned to evaluate the 
safety of MRX34 in patients with selected solid tumors or 
hematologic malignancies (Fig. 6) (ClinicalTrials.gov MRX34- 
102).The usage of miR mimics for systemic delivery is challenging 
compared to anti-miR drugs. MiR mimics need to be double-stranded 
in order to be processed correctly by the cellular RNAi-machinery 
and therefore cannot be administered “naked”. Successful delivery 
therefore requires complex delivery vehicles mimicking 
physiological settings where miRs reside in microvesicles or 
exosomes. For MRX34, miR therapeutics has developed custom 
nanoparticle liposomes. According to company information (MIRNA 
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THERAPEUTICS) these liposomes increase stability, enhance 
delivery and prevent immune response effects.
Figure 6. Clinical trial of miR-34. ClinicalTrials.gov is a registry and 
results database of publicly and privately supported clinical studies 
conducted around the world.  
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1.11 MiR-221 and miR-222. 
Recent evidence indicates that miRs play a crucial role in the 
initiation and progression of human cancer. Specifically several 
groups have focused their attention on miR-221 and miR-222 
demonstrating their capability to act as oncogenes.  
MiR-221 and miR-222 are clustered on the X chromosome and 
transcribed in a common precursor of 2.1 kb RNA, suggestive of a 
coordinate functional role. Their upregulation has been reported in 
many types of cancers in comparison with their normal counterparts 
(Sun T. , 2009; Ciafrè S.A., 2005; Visone R., 2007; Zhang J., 2010, 
Garofalo M., 2009; Miller T.E, 2008; Medina R., 2008; Felicetti F., 
2008). Specifically, Felicetti and co-workers reported miR-221&222 
increasingly expressed during the multistep process from normal 
melanocytes to advanced metastatic melanomas (Felicetti F., 2008). 
To demonstrate the functional role of miR-221&222, they used a 
lentiviral vector system to over-express both miRs in a moderately 
aggressive melanoma cell line, selected on the basis of its low but 
detectable levels of miR-221&222 and of its ability to produce 
melanin, a function often lost in more advanced melanomas. As a 
direct effect, the ectopic miR-221 and miR-222 expression resulted 
in a significant increase in the proliferative growth rate, in the 
invasive and chemotactic capabilities, as well as in the anchorage-
independent growth. They also confirmed the induction of a more 
tumorigenic phenotype by miR-221&222 in an in vivo model: tumor 
volumes of miR-221&222-expressing melanoma cells were 
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increased when compared with controls. More important, silencing 
of miR-221&222 in metastatic melanoma cells by chemically 
modified oligomers (antagomirs) inhibited the main functional 
properties associated with advanced melanomas in vitro and in vivo 
(Felicetti F., 2008). These findings suggest the inhibition of miR-
221&222 as an attractive approach for translation into the clinical 
setting, particularly important in advanced melanoma still lacking 
long lasting effective treatments. Accordingly, other studies reported 
the feasibility and safety of prolonged administration of a locked 
nucleic acid (LNA)–modified phosphorothioate oligonucleotides that 
antagonize the function of a specific miR in a highly relevant disease 
model of chronic hepatitis C (Lanford RE., 2010).  
In melanoma miR-221 and miR-222 have been reported to exert their 
function by repressing p27Kip1 and c-KIT receptor, and even more 
important AP2α, thus promoting cells proliferation and 
differentiation blockade (Felicetti F., 2008, Igoucheva O., 2009, Felli 
N., 2016). p27Kip1 is a cell-cycle regulatory protein that interacts 
with cyclin-CDK2 and -CDK4, inhibiting cell cycle progression at 
the G1/S checkpoint. Almost certainly miR-221&222 binding to the 
3’UTR of p27Kip1 is favored by Pumilio-1 (PUM-1), an 
ubiquitously expressed RNA-binding protein highly stable in cycling 
cells that inducing a local conformation change in the p27Kip1 
transcript makes it accessible to miR regulation (Kedde M., 2010). In 
addition Fornari and co-workers have shown that the down-
modulation of another member of CDKIs, p57, was associated with 
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miR-221 upregulation and increased aggressiveness in human 
hepatocarcinoma (Fornari F., 2008), thus further substantiating the 
biological significance of miR-221 and miR-222 as cell cycle 
regulators. The miR-221&222 contribution to melanogenesis is 
exerted by repressing the c-KIT tyrosine kinase receptor (Felicetti F., 
2008). The SCF/c-KIT signaling pathway is essential during 
melanocytes migration from the neural crest to the skin. C-Kit 
receptor for the stem cell factor (SCF) plays an important role in 
melanogenesis, cell growth, migration, and survival (Alexeev V., 
2006). Ubiquitously expressed in mature melanocytes, c-KIT is 
downregulated in approximately 70% of metastases, allowing 
melanoma cells to escape the SCF/c-KIT–triggered apoptosis 
(Willmore-Payne C., 2005). The transduction signal generated by 
SCF/c-KIT interaction induces the activation of the Microphthalmia-
associated transcription factor (MITF) protein (Shin SH., 2013), 
known to regulate a broad repertoire of genes whose functions in 
melanocytes range from development, differentiation, survival, cell-
cycle regulation and pigment production. In particular, MITF 
controls the melanin production directly regulating the main 
melanogenic enzymes such as tyrosinase (TYR) and, tyrosinase-
related protein 1 (TYRP1). These notions indicates that, miR-
221&222 suppress the expression of c-KIT, producing a subsequent 
downstream inhibition of the MAPK signaling cascade resulting in 
the decrease of MITF, TYR and TRP-1. The regulation of MITF 
expression in melanoma cells appears extremely complex as, 
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according to a proposed model, MITF high levels result in cell cycle 
arrest and differentiation, intermediate levels promote proliferation 
and tumorigenesis, whereas low  amounts lead to cell cycle arrest 
and apoptosis (Wellbrock C., 2005; Goding G., 2006; Gray-Shopfer 
V., 2007; Hoek KS., 2010). Therefore miRs, as miR-221&222, miR-
137 or miR-148/152, should tightly adjust MITF at the favored 
levels. Consistent with this regulation, there is less MITF expressed 
in melanoma cells than in normal melanocytes (Haflidadóttir BS., 
2010; Felicetti F., 2008).  
We recently demonstrated AP2α, required for preventing the 
progression of cutaneous melanoma, as an additional target of miR-
221&222. Although the expression of AP2α protein is lost in the 
majority of malignant melanoma cell lines (Bar-Eli M., 1997), its 
mRNA is still present in the same cells, indicating that AP2α should 
be mostly regulated at post-transcriptional level. A miR-221&222-
mediated inhibitory role was suggested by the inverse correlation 
between AP2α and these two miRs and then confirmed by reporter 









Also miR-221&222 were reported to directly target the tumor 
suppressor PTEN in NSCLC (Garofalo M., 2009) and the 
proapoptotic protein PUMA in glioblastoma (Zhang C., 2010). Given 
that PUMA expression is dramatically reduced in metastatic 
melanomas compared to primary melanomas (Karst A.M., 2005) and 
the loss of PTEN function seems to be responsible for many of the 
phenotypic features of melanoma (Aguissa-Touré H., 2011), it would 
be important to study if both PUMA and PTEN are downregulated 
Figure 7. AP2α targeting by miR-221&222. Western Blot  
analysis of AP2α with relative densitometric evaluation and miR-
221 and -222 levels in normal melanocytes (NHEM) and 
melanoma cell lines. 
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by miR-221&222 also in melanoma, adding a new small piece in the 
elucidation of the complex mechanism of regulation. 
All together it is significant to evidence that most of miR-221&222 
direct targets play antineoplastic functions (Fig. 8). 
1.12 Regulation of microRNA transcription: the example of miR-
221&222. 
Not much is known on transcriptional regulation of specific miRs. 
The majority of miRs are transcribed by RNA Pol II and many 
characteristics of miR gene promoters, such as the relative 
frequencies of CpG islands, TATA box, TFIIB recognition, initiator 
Figure 8. Representative genes targeted by miR-221&222 in 
cancer. MiR-221&222 are key factors for tumor development and 
dissemination,  as they control the progression of the neoplasia 
through the down-modulation of several direct key targets. 
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elements, are similar to the promoters of protein coding genes. 
Although their individual regulatory machinery has not been finely 
studied yet, the DNA-binding factors that regulate miR transcription 
largely overlap with those that control protein-coding genes.  
Among diverse miRs, particular attention has been paid on the 
transcriptional regulation of miR-221&222 in different types of 
cancers, including melanoma, where different groups evidenced both 
positive and negative regulators of transcription (Garofalo M., 2009).  
These regulatory binding sites have been identified in the putative 
promoter region upstream to pre-miR-222 between -400 and -50 bp 
(Felicetti F., 2008; Di Leva G., 2010; Mattia G., 2011). Felicetti and 
colleagues highlighted the first negative regulation system of miR-
221&222 transcription played by the transcription factor in 
melanoma cell lines. PLZF is a tumor suppressor gene, barely or not 
detectable in melanomas, but expressed in normal melanocytes. A 
clear down-regulation of both miRs, paralleled by a more 
differentiated melanocyte-like phenotype, was observed when PLZF 
was reexpressed in melanoma cells. Two putative consensus binding 
sequences for PLZF are located upstream to pre-miR-222 and a third 
site is localized in the intragenic region between the two miR 
sequences. Promoter luciferase and ChIP assays confirmed the 
capability of PLZF to bind the consensus sequences upstream to 
miR-221&222, negatively regulating their expression. Thus, in 
advanced melanomas the lack of PLZF allows miR-221&222 up-
modulation and, in turn, melanoma progression (Felicetti F., 2008).  
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A more complex function is played by ETS-1(v-ets erythroblastosis 
virus E26 oncogene homolog 1) on miR-221&222 regulation (Mattia 
G., 2011). ETS-1 transcription factor is the founding member of the 
ETS gene superfamily, encoding a class of phosphoproteins 
characterized by a conserved domain that recognizes and binds to a 
GGAA⁄T DNA core sequence. ETS-1 is involved in an array of 
cellular functions and, dimerizing with different partners, it can play 
either positive or negative functions (He J., 2007; Nakayama T., 
1999). The complexity of ETS-1 action has been well demonstrated 
by the authors that reported either negative or positive regulation on 
miR-221&222 transcription, in early and advanced melanoma cells, 
respectively. ETS-1 post-translational modifications, rather than its 
total protein content, seem to be functionally relevant. In fact, taking 
in mind the activating phosphorylation at Thr38, in low grade 
malignant cells the significant amounts of barely or not 
phosphorylated ETS-1 represses miR-221&222 transcription. 
Conversely, in metastatic melanomas the persistent activation of the 
MAPK-ERK1⁄2 cascade increases the fraction of Thr-38 
phosphorylated ETS-1 inducing miR-221&222 transcription and 
possibly tumor malignancy. Bioinformatic analyses showed the 
presence of a canonical seed for miR-221&222 in the 3’UTR of 
ETS-1. Interestingly, ETS-1 resulted directly targeted by miR-222, 
but not by miR-221, thus indicating the capabilities of these two 
miRs to play some independent functionality in addition to the 
common ones (Mattia G., 2011).  
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The AP-1 transcription complex, characterized by c-Jun and c-Fos 
heterodimerized proteins, is predicted to bind and transcriptionally 
activate miR-221&222 promoter. In metastatic melanomas, the ERK 
constitutive signaling activates c-JUN (Lopez-Bergami P., 2007) and 
P-T38-ETS-1 (Yang BS., 1996), which in turn cooperates towards 
miR-221&222 activation (Garofalo M., 2009; Mattia G., 2011).  
Recently, a report by Galardi and co-authors showed that the ectopic 
modulation of NF-kB modifies miR-221&222 expression in prostate 
carcinoma and glioblastoma cell lines (Galardi S., 2011). The 
identification of two separate distal regions upstream of miRNA-
221&222 promoter bound by the NF-kB subunit p65 and driving 
efficient transcription have been demonstrated. In this distal enhancer 
region it has been defined a second binding site for c-Jun that 
cooperates with p65 fully accounting for the observed up-regulation 
of miRNA-221&222. Thus, this study finds out an additional 
mechanism through which NF-kB and c-Jun, two transcription 
factors deeply involved in cancer onset and progression, contribute to 
oncogenesis by promoting miR-221&222 transcription. Whether or 
not this distal enhancer regulatory region is also involved in miRNA-
221&222 transcriptional regulation also in melanoma has to be 
investigated. 
Furthermore, Ozsolak and coworkers reported a number of miRs, 
including miR-221&222, to be regulated by MITF in melanoma cells 
by using nucleosome mapping and linker sequence analyses 
(Ozsolak F., 2008). 
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Finally, Howell and co-workers reviewed positive and negative 
feedback loops involving miR-221&222 transcriptional regulators 
and targets (Howell PM., 2010). Specifically, they described the 
miR-221&222 involvement in melanoma progression as the result of 
both p27Kip1 and PTEN inhibition. As a consequence of p27Kip1 
reduction, cyclin-dependent kinase 2 (CDK2) mediates PLZF 
phosphorylation, thus causing its ubiquitination and degradation. In 
addition PTEN reduction promotes the binding of the astrocyte 
elevated gene 1 (AEG-1) to PLZF, preventing it from its 
transcriptional repressive action. 
1.13 MiR-34 family. 
In mammalians the miR-34 family comprises three processed miRs 
that are encoded by two different genes: miR-34a is encoded by its 
own transcript, whereas miR-34b and miR-34c share a common 
primary transcript (Hermeking H., 2010). The importance of 
studying miR-34 family members in cancer is directly linked to p53 
functions, the most important tumor suppressor gene, frequently 
silenced or inactivated in cancer, and directly connected to increased 
metastatic potential. Different types of DNA double-strand breaks 
promote accumulation and increased transcriptional activity of p53, 
whose level directly mediates either cell cycle arrest or apoptosis in 
consideration of the presence of light or severe DNA damage 
(Hollstein M., 1991; Vogelstein B., 2000; Oren M., 2003). Reports 
from several laboratories have shown that members of  miR-34 
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family are directly regulated by p53 (Heinemann A., 2011).  Recent 
data define a new role for p53 and suggest that p53 specifically 
modulates the tumor immune response by regulating PDL1 via miR-
34 (Cortez M.A., 2016). In addition the up-regulation of miR-34a/b/c 
induced cell-cycle arrest and apoptosis, suggesting these miRs as 
effectors of p53 functions (Chang TC., 2007; Raver-Shapira N., 
2007; Tarasov V., 2007).  
Examples of genes targeted by miR-34 family members include 
CDK4/6, Cyclin E2, MET and Bcl-2 (Fig. 9) (He L., 2007).  
So miR-34 induction allows p53 to regulate tumor suppressive 
mechanisms through cell cycle arrest, senescence or apoptosis. On 
the contrary, miR-34 inactivation may be a selective advantage for 
cancer cells. Downregulation of miR-34a was reported in 
Figure 9. Cellular outcomes associated with miR-34a-induced gene 
silencing.  Representation of the main miR-34a target mRNAs, and 
biological effects associated with their repression.  
Misso, 2014. 
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neuroblastoma tumors harboring 1p36.3 loss and in chronic 
lymphocytic leukemia patients carrying 17p13/TP53 
deletions compared with patients without such deletions. Loss of 
1p36, the genomic interval harboring miR-34a, is common in diverse 
human cancers, but one of the other mechanisms responsible for 
decrease of miR-34 family expression levels seems to be CpG island 
hypermethylation (Misso G., 2014). 
Bisulfite sequencing confirmed a heavy methylation in prostate as 
well as in pancreatic, breast and malignant melanoma cell lines. 
Accordingly, in the IGR-39 melanoma cell line expressing wild-type 
p53, CpG methylation of miR-34a regulatory region did not allow 
p53 induction of miR-34a, even after etoposide treatment. This result 
might explain how miR-34a methylation could underlie the selective 
advantage for cancer cells (Lodygin D., 2008). CpG methylation of 
miR-34a/b/c was found in malignant melanoma, but not in normal 
melanocytes, in good connection with the metastatic potential and 
the induction of epithelial-mesenchimal transition (EMT) 
(Siemens H., 2011).  
Since p53 inhibition of EMT has been described as a mode of tumor 
suppression which presumably prevents metastasis (Hwang S., 
2011), the frequent inactivation of p53 and/or miR-34a/b/c found in 
cancer, may shift the equilibrium of these reciprocal regulations 
towards the mesenchymal state, thereby blocking the cells in a 
metastatic state (Siemens H., 2011).  
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It is also important to mention that another member of the p53 
family, p63, correlating with the growth and regenerative capabilities 
of keratinocytes directly depends on miR-34a and -34c repression 
(Antonini D., 2010). MiR-34a has also been indicated as a potential 
tumor suppressor in uveal melanoma where it is prevalently silenced. 
Its enforced expression led to a significant decrease in cell growth 
and migration with reduction of c-Met mRNA expression and 
therefore down-regulation of phosphorylated Akt and cell cycle 
related proteins (Yan D., 2009). 
Tumor cells can escape from NKG2D immune surveillance by an 
enhanced proteolytic shedding of the NKG2D ligand ULBP2 (Groh 
V., 2002). Accordingly elevated levels of soluble ULBP2 in sera 
from melanoma patients have been reported as strong independent 
predictors of poor prognosis (Paschen A., 2009). Experimental 
proofs indicate that miR-34a and miR-34c control ULBP2 expression 
and that level of miR-34a inversely correlated with expression of 
ULBP2 surface molecules. Finally, different experimental data 
indicate that miR-34 family per se might have diagnostic or 
prognostic potential and can be possibly used as predictor of therapy 
response in different tumor types. The group around Dr. Scotlandi 
defined a signature of five miRs, including miR-23a, miR-92a, miR-
490-3p, and miR-130b, besides miR-34a, as an independent predictor 
of risk to disease progression and survival in Ewing’s sarcoma 
patients. Results were particularly robust for miR-34a, which 
appeared associated to either event-free or overall survival: patients 
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with the highest expression of miR-34a did not experience adverse 
events in  five years, whereas patients with the lowest expression 
recurred within two years (Nakatani F., 2012). 
1.14 Circulating microRNAs. 
Circulating miRs have been detected in both plasma and serum of 
healthy and diseased subjects, where they represent potential 
noninvasive molecular markers. In order to actually utilize miRs as 
accurate predictors of cancer, a number of points should be evaluated 
more in depth. In fact, although it is realistic to directly and 
consistently amplify miRs from serum avoiding RNA extraction, 
difficult quantification and the lack of representative internal controls 
still represent a drawback. 
As ribonucleases are highly present in body fluids, the presence of 
circulating miRs suggests that they are mostly included in lipid or 
lipoprotein complexes, such as apoptotic bodies, microvesicles or 
exosomes resulting, therefore, protected (Skog J., 2008). These 
extracellular RNAs appear to be involved in cell-cell and cell-
microenvironment communication, providing a useful tool for 
studying the genetic changes relative to tumor progression simply 
analyzing serum samples (Kosaka N., 2010). 
Different circulating miRs have been associated with specific types 
of cancers, serum miR-221 has been reported as a possible tumor 
marker of metastatic melanoma (Kanemaru H., 2011). MiR-17-5p, 
miR-21, miR-106a and miR-106b have been reported to be 
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upregulated in plasma of patient with gastric cancer.  Hu et al. 
discovered that the expression level of miR-486, miR-30d, miR-1 
and miR-499 was associated with overall survival of non-small-cell 
lung cancer (NSCLC). These miRs have been proposed to 
successfully predict patient survival by identifying high-risk and 
low-risk groups of cancer death. Furthermore serum from patients 
with diffuse large B-cell lymphoma (DLBCL) contained elevated 
levels of tumor associated miRs specifically miR-155, miR-210 and 
miR-21 in comparison to healthy control (Weiland M., 2012). 
Melanoma EXOs and microvesicles have already been already 
shown to exert paracrine functions possibly to prepare the neigh 
boring microenvironment to metastatic dissemination. Results 
demonstrated that EXOs can act on endothelial cells by inducing a 
proangiogenic program and on sentinel lymph nodes by regulating 
inflammatory cytokines (Hood JL., 2011).  In the last years, literature 
is indeed flourishing with examples proving the role of tumor EXOs 
in the transfer of growth factors and cognate receptors to 
homologous or heterologous target cells (Camussi G., 2010). In 
particular, in melanoma cells functional studies have confirmed the 
competence of these microvesicular particles to convey the 
metastatic assets of an advanced donor melanoma into a less 
aggressive recipient cell line (Felicetti F., 2009). Furthermore Yuan 
et al. have shown that microvesicles derived from embryonic stem 
cells may also transfer their subset of miRs in an acceptor cell 
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population of fibroblasts consequently altering the expression levels 
of miR target mRNAs in surrounding cells (Yuan A., 2009).  
1.15 Therapeutic potential of microRNAs. 
Since abnormal miRs expression appears in many disease states 
including cancer, it is possible that miRs could be used as therapeutic 
targets or as therapies themselves. For inhibiting tumor promoting 
miRs, single stranded chemically modified miR antagonists can be 
delivered systemically and, without a delivery vehicle, they are able 
to distribute to diverse tissue types such as the kidney, liver, lymph 
nodes, bone marrow and spleen (Jackson A., 2010). 
Experimentally, it has been demonstrated that miR inhibition is 
possible in in vivo animal models. Inhibition of miR-122, a miR 
abundant in the liver, via systemic administration of a miR-122 
antisense oligonucleotide can result in reduced levels of plasma 
cholesterol and decreased hepatic fatty acid and cholesterol synthesis 
in normal mice (Esau C., 2006). Therapeutic miR inhibition has also 
been demonstrated in primates where abrogation of miR-122, 
essential for replication of Hepatitis C virus in liver cells, resulted in 
an approximate 80% reduction of its replication (Lanford R., 
2010). Conversely, for miRs reduced in disease states, their 
replacement could provide a therapeutic benefit through 
restoration of target genes. 
MiRs also represent ideal molecules for use in gene therapy as they 
exert their function once in the cytoplasm of the targeted cell. There 
are several experimental examples of tumor suppressor miR 
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therapeutic efficacy in animal models. Let-7 is a miR which exerts its 
effect mainly through on the RAS oncoprotein being expressed at 
lower levels in different cancer tissues compared to normal lung 
tissue, including non-small cell lung cancer tissue (Johnson SM., 
2005; Bader A., 2010). Functional studies in mouse models have 
shown delivery of let-7a blocks proliferation of cancer cells and 
reduces growth of the existing tumor (Trang P., 2010;Wiggins J., 
2010). 
No significant concerns over toxicity have been related to systemic 
delivery of miRs. Nonetheless the effects of accumulation of 
exogenous miRs in normal cells and tissues are not known. It has 
been suggested that toxic effects could occur due to overloading of 
cellular machinery with exogenous miRs resulting in competition 
with endogenous ones, essential for normal cellular functions and 
homeostasis. In addition, miRs target multiple mRNAs and certain 
miRs with desired effects on one target gene may produce a 
deleterious effect on a multitude of other genes. Anyhow studies in 
murine models of systemically delivered miRs have failed to 
demonstrate any serious adverse effects thus far (Johnson SM., 2005; 
Bader A., 2010). Overall, miR therapeutics appears a highly 
promising new therapeutic method. The most significant challenge, 
however, lies in the area of in vivo delivery. Vehicles to efficiently 
and specifically delivery miRs to recipient cells are required, and 
EXOs might represent one of them as they easily cross biological 
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barriers, are naturally taken up by cells and can transfer their cargo, 
including miRs. 
1.16 Melanoma. 
Cutaneous melanoma is an aggressive neoplasia whose incidence is 
steadily increasing being the number of melanoma cases worldwide 
rising faster than any other cancer. Screening and early detection are 
still the best prognostic factors leading to 99% of favorable outcome 
if the primary lesion is detected very early (more than 90% survival 
in stage I melanomas). Melanoma that has disseminated to distant 
sites and the visceral organs is almost always incurable, with a 
median survival time of only 6–9 months, a 25% 1 year survival rate, 
and a 3 year survival of 15% (Eggermont AMM., 2014).This fact 
gets even more aggravating, considering that metastases to distinct 
organs are very early events in the progression of this disease. It is 
then obvious how important might be to study in depth the molecular 
oncogenic pathways implicated in transformation and progression in 
order to identify new representative markers for diagnosis, prognosis 
and eventually therapeutic treatments. Several melanoma 
biomarkers, such as the mitotic and the Ki-67 marker expression 
indexes, have been evaluated for their prognostic utility (Vereecken 
P., 2007), but to date none has been proven to be really clinically 
useful in large-scale studies (Larson AR., 2009). Although several 
molecular abnormalities have been associated with melanoma 
progression, as the loss of AP-2 transcription factor (Huang S., 1998) 
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or the high mutation rate of the B-RAF oncogene (Dhomen N., 
2007), the mechanisms underlying the differential gene expression 
are still largely unknown and the conventional histological 
classification remains the best prognostic factor (Clark WH., 1984).  
The Clark model describes the histological changes that accompany 
the progression from normal melanocytes to malignant melanoma 
(Fig. 10).  
In this model, five distinct steps of melanoma development and 
progression are distinguished: a mature melanocyte acquires 
mutations that lead from benign (Step 1) to dysplastic nevi (Step 2). 
The subsequent radial growth phase (RGP) primary melanoma (Step 
3) is the first recognizable malignant stage in which cells do not
Figure 10. Clark’s model. Representative  steps showing the main 
histological and genetic changes from normal melanocyte to 
malignant melanoma. 
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possess metastatic potential, but are already locally invasive. RGP is 
followed by the vertical growth phase (VGP) (Step 4), in which 
melanoma cells infiltrate and invade the dermis showing metastatic 
potential. This process finally results in metastases to distant organs 
by an overgrowth of disseminated tumor cells at these sites (Step 5) 
(Gray-Schopfer V., 2007). The main clinical and histopathological 
prognostic factors that are currently in use for melanoma include 
tumor depth (i.e. Breslow thickness), diameter, ulceration, anatomic 
site (i.e. acral, mucosal, cutaneous) and sentinel lymph-node status 
(Balch CM., 2001). The identification of other molecules as 
representative prognostic or diagnostic markers and, eventually, as 
new targets to aim at in new therapeutic approaches is therefore 
particularly relevant. 
1.17 Ewing’s sarcoma. 
Ewing’s sarcoma (EWS) is the second most common bone tumor in 
pediatric age. It is an aggressive, poorly differentiated neoplasia with 
elevated tendency to give lung and/or bone metastases.  Despite the 
use of intensive, multimodality therapy, the prognosis of patients 
with metastatic EWS remains grim (survival of 40% even with 
intensive chemotherapy) and few treatments can be offered to those 
who relapse after first-line therapies. Even for children who are 
cured, the long-term morbidity of cytotoxic treatment is substantial, 
indicating the need of new therapeutic strategies for this disease 
(Womer RB., 2012; Ginsberg JP., 2010). From a genetic point of 
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view, EWS is characterized by highly recurrent translocations 
involving ETS transcription factors, with EWS-FLI1 
t(11;22)(q24;q12) and EWS-ERG t(21;22)(q22;q12) fusion proteins 
being the most common (Fig. 11).  
EWS-FLI1 functions as an aberrant transcription factor that regulates 
crucial processes such as cell growth, apoptosis and differentiation 
through induction or repression of specific target genes and 
represents the oncogenetic driver of EWS. Forced expression of 
EWS-FLI1 in human mesenchymal stem cells, the closest EWS-
related normal cell type, was demonstrated to be sufficient to 
Figure 11. Gene rearrangements involved in Ewing’s sarcoma. 
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transform cells and induce a gene expression profile similar to that 
observed in EWS cells, whereas deprivation of EWS-FLI1 in EWS 
cells resulted in a gene expression signature overlapping with 
mesenchymal progenitor cells. The characterization of EWS 
genomes has poorly contributed to the identification of novel 
therapeutic strategies. EWS shows very low rate of somatic 
mutations (Crompton B.D., 2014; Tirode F., 2014; Delattre O., 
1992), confirming the dependence of this tumor on the oncogenic 
chimeric EWS–FLI1 protein. The membrane glycoprotein CD99 is 
also present at high levels in all the cells and both EWS-FLI1 and 
CD99 proteins concur to the pathogenesis of EWS, maintaining the 
cells in a de-differentiated state. EWS-FLI1 oncogenic activity is 
facilitated by CD99 and, consistently, EWS-FLI1 maintains high 
levels of CD99 expression, either directly through binding of CD99 
promoter or indirectly through miR regulation (Rocchi A., 2010; 
Franzetti G.A., 2013). However, as a transcription factor, EWS–FLI1 
is a puzzling drug target (Kovar H., 2014), and current therapy of 
EWS still depends on conventional cytotoxic drugs with no 




Exosomes (EXOs) are part of the endogenous intracellular 
communication system. Their stimulatory and inhibitory signaling 
activities are mediated by their content (mRNAs, miRNAs and 
proteins) that can be transferred from the cell of origin to recipient 
cells influencing cellular activities and the surrounding 
microenvironment. 
This study aimed to evaluate the capabilities of EXOs released by 
tumor cells, either melanoma or Ewing’s sarcoma, to influence 
cancer growth and/or metastasis through the horizontal transfer of 
their cargos. Based on these data and on growing amounts of 
literature, it is important to emphasize that the distance covered by 
miR-enriched or miR-depleted EXOs induces broad effects on the 
entire tumor cell populations, thus representing a promising 
opportunity for novel therapeutic applications. 
In particular we looked for the tumorigenic properties associated 
with miR-222 assessing: 
 whether the presence of increased levels of miR-222 into
melanoma-released EXOs was sufficient to transfer the
aggressive behavior of the donors into the acceptor cells;
 the key downstream pathways and potential representative
biomarkers;
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 the option of modulating the exosomal cargo as a consequence
of miR-221&222 abrogation.
We also evaluated the role of Ewing’s sarcoma-derived EXOs as 
mediators of signals involved in cancer growth, metastases and 
differentiation focusing on: 
 the different properties associated with EXOs secreted by
sarcoma cells silenced for membrane glycoprotein CD99 in
comparison with control cell lines;
 the functional role of EXO-vehicled miR-34a in inducing neural
differentiation in recipient Ewing’s sarcoma cells.
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3. RESULTS
3.1 Purification and characterization of exosomes. 
EXOs were purified from conditioned media of 24 hours cell cultures 
of melanoma and Ewing’s sarcoma cells. In the initial phase of the 
study we used the classic method based on differential 
ultracentrifugation (UC). This system consists of several 
centrifugation steps aiming to eliminate dead cells, large debris and 
others particles to keep only small vesicles, ranging between 70 and 
140 nm. In a parallel set of experiments, we utilized a commercial 
Polymer-based precipitation system -ExoQuick™ TC- (EQ) (Fig. 
12a). This kit, founded on mixing the conditioned media with 
polymer-containing precipitation solution, incubation step and 
centrifugation at low speed, is easy and fast to perform and allow 
selecting highest amounts of EXOs. 
Looking for their purity, both vesicle preparations were compared. 
Vesicles were evaluated for their size distribution by using the 
Nanosight™ technology and the Nanoparticle Tracking Analysis 
(NTA) software that characterizes nanoparticles from 10 nm to 2000 
nm in liquid suspension samples. Each particle is individually, but 
simultaneously analyzed by direct observation and measurement of 
diffusion events. This particle-by-particle methodology produces 
high resolution results for particle size distribution and concentration 
(Fig. 12b left). 
Results showed similar profiles for UC- and EQ-derived EXOs, with 
nanoparticles characterized by the expected sizes with mean values 
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around 100 nm. In addition the amount of tumor-released EXOs was 
assessed by using either the Nanosight™ technology or the Bradford 
assay for protein quantization (Fig. 12b). 
EXOs derived from both cellular models were also analyzed by 
western blot for the enrichment of proteins commonly used as 
exosomal  markers (Fig. 12b), such as the lysosomal protein 
(LAMP2), the heat shock protein (HSP90), the tetraspanins (CD63, 
CD81),  the membrane transport and fusion proteins (RAB5B, 
RAB27A) and TSG101. As internal loading controls, we utilized β-
ACTIN which appeared constantly expressed and carried by the 
EXOs.  




Figure 12. EXOs purification and characterization. a) Flow chart 
outlining the main steps of exosome isolation from cell culture 
supernatants. EXOs were purified from 24h cell culture media by 
ultracentrifugation (UC) (left panel) or Exoquick-TC (EQ) (right 
panel) methods. b) Size distribution of UC and EQ purified vesicles 
analyzed by the Nanosight™ technology. Structure and contents of 
EXOs. 
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3.2 MiR-221 and 222 in melanoma cell lines. 
As previously reported (see Introduction and Felicetti F., 2008), 
different data obtained in our lab clearly indicated that the expression 
of miR-221 and miR-222 correlates with melanoma progression. 
First of all these miRs are almost undetectable in normal human 
melanocytes and increasingly expressed throughout a stepwise 
transformation process, as shown by northern blot, qRT-PCR and in 
situ hybridization analyses (Fig. 13a). These miRs controls the 
progression of the neoplasia by repressing p27Kip1 and c-KIT 
receptor, leading to enhanced proliferation and differentiation 
blockade of the melanoma cells, respectively. Different functional in 
vitro (migration, invasion and colony growth in agar) as well as in 
vivo experiments, by using miR- and empty vector–transduced 
Me1402/R cell lines to subcutaneously inject athymic nude mice, 
confirmed the key role of miR-221&222 in increasing malignancy of 
human melanomas (Fig. 13b). These results were also confirmed by 
treatment with antagomir oligonucleotides that strongly reduce cell 





Figure 13. Expression of  miR-221&222 in melanoma cells. a) 
Northern, q-RT PCR  and in situ hybridization. MiR-221 and -222 
were almost undetectable in normal human melanocytes and 
increasingly expressed throughout a stepwise transformation    
process. b)  invasion, migration and proliferation assays. c)In vitro and 
in vivo treatment with antagomiR-221&222. 
Figure 13 
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3.3 MiR-222 in melanoma purified exosomes. 
MiR-222 was found to be carried by EXOs derived from different 
tumors, including breast, thyroid and ovary (Yu DD., 2016; Lee JC., 
2015; Ying X., 2016). In view of the tumorigenic role played by 
miR-222 in melanoma, we evaluated the presence of miR-222 and 
the possible associated properties in EXOs released by differently 
staged melanoma cell lines in their culture media.  
For this reason EXOs were purified by UC or EQ methods from 
conditioned media of stabilized and early passage melanoma cell 
lines at different stages of progression. Total RNAs were extracted 
using a specific RNA MicroKit that allows extracting from small 
amounts of biological material. RNA quality will be assessed and 
only samples with UV absorbance ratios 260/280 ≥2.0 and 260/230 
between 1.8 and 2.2 accepted. 
According to the general trend of miR-222 enhancement associated 
with melanoma advancement (Felicetti F., 2008), qRT-PCR analysis 
revealed that EXOs, either UC- or EQ-purified, released by 
metastatic cells contained higher levels of miR-222 in comparison 
with primary melanomas (Felicetti F.  De Feo A. 2016) (Fig. 14a). 
This differential expression pattern was confirmed in melanoma cells 
analyzed at early times after surgical excision and in the 
corresponding released EXOs (Fig. 14b), thus ruling out any possible 
artifact due to cell cultures. MiR-16 is used as an internal control, 
because it is highly expressed and relatively invariant across our 
melanoma cell lines. 
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Figure 14.  MiR-222 expression analysis in melanoma EXOs. MiR-
222 levels were compared by qRT-PCR in a) stabilized melanoma cell 
lines and corresponding EXOs either UC (EXO UC) or EQ (EXO EQ) 
purified and b) in early passages melanoma cells and corresponding 
EXOs. Me1007 primary melanoma cell line was used as an internal 
control to compare the two groups. Columns, mean±SD of at least three 
independent experiments. 
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To investigate the functionality of miR-222 in EXO mediated 
tumorigenesis, we selected two melanomas, Me1007 and Me1402/R, 
early primary and recurrence of primary melanoma, respectively. 
These two melanoma cell lines, characterized by low endogenous 
levels of miR-222 were lentivirally transduced either with Tween 
control vector or with miR-222 (Felicetti F., 2008). 
qRT-PCR analysis confirmed the significant relative up-regulation of 
miR-222 in miR-transduced Me1007 and Me1402/R (10-fold and 12-
fold, respectively) in comparison with levels detected in vector-
transduced melanoma cell lines (Fig. 15a). Notably, similar 
increments of miR-222 were detected in the corresponding EXOs (6-
fold for EXOs secreted by Me1007 and 12-fold for those released by 
Me1402/R) (Felicetti F. De Feo A. 2016) (Fig. 15a). 
The amount of secreted EXOs was then assessed by using either the 
Nanosight™ technology or the Bradford assay for protein 
quantization. Both techniques revealed that miR-222-transduced 
melanomas secreted a significantly higher number of EXOs 
compared with control cells. These results, besides being in 
agreement with the higher malignancy associated with miR-222 
overexpression, might also suggest a role for this miR in the EXO 
releasing process (Fig. 15b). 
In addition, a technique recently developed at the Istituto Superiore 
di Sanità (Coscia C., 2016) further support this effect. This new 
method is based on a unique fluorescent phospholipid labeling 
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procedure which allows estimating EXO number, diameter and 
fluorescent intensity via cytometer analysis. Control or transduced-
miR-222 cells were labeled by including into the culture medium the 
green fluorescent fatty acid molecule BODIPY® FL C16a, precursor 
of a variety of phospholipids, which, being incorporated into cell 
membranes, made possible EXOs’ labeling. After 5 h of incubation 
the dye in excess was washed out and cell culture media containing 
Fluo-EXOs was recovered. Fluo-EXOs were then purified and 
examined by cytometer analysis. 
The protein content of these EXOs analyzed by western blot showed 
a miR-222-dependent enrichment for proteins commonly utilized as 
exosomal markers, such as LAMP2, HSP90, CD63, and membrane 
transport and fusion proteins, such as RAB5B (Fig. 15c). In addition, 
according to miR-222 overexpression into the exosomal cargo (Fig. 
15a), we observed reduced levels of p27Kip1, a negative regulator of 
cell cycle previously demonstrated as a direct target of this miR (Fig. 
15c) (Felicetti F., 2008). Of note the EXO-dependent downregulation 
was comparable to that obtained by miR-222 enforced expression. 
These results suggested that miR-222 was somehow functional in the 
vesicular fraction (Fig. 15c). Accordingly, in EXOs released by 
Me1402/R we detected a miR-222-dependent increase of CAV-1 and 
RAB27A, proteins already described for their involvement in EXO 
uptakes and secretory pathways in melanoma (Felicetti F., 2009; 
Logozzi M., 2009; Peinado H., 2012). Although CAV-1 and 
RAB27A are expressed in Me1007 cells, we were unable to detect 
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them in the corresponding EXOs, likely because of their low levels. 
As internal loading controls, we utilized TSG101 and β-ACTIN 
which appeared constantly expressed (Fig.15c). 
Figure 15 
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Figure 15. Characterization of melanoma EXOs. a) 
Representative qRT-PCR in miR-222- and empty vector-
transduced melanoma cells and corresponding exosomes 
(EXO). Relative miR expression levels were normalized on 
miR-16 (for EXOs) or RNU6B (for cells). b) The relative 
amounts of melanoma-derived EXOs were assessed by using 
the Nanosight™ technology (left) or by the Bradford assay for 
protein quantization (right). c) WB analysis of specific ‘‘EXO-
enriched’’ proteins in EXOs purified from Me1007 and 
Me1402/R melanomas by the EQ method. β-Actin was utilized 
as internal loading control for each experiment. Columns, 
mean±SD of at least three independent experiments. * p < 0.05; 
** p < 0.01. 
Figure 15 
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3.4 Evaluation of exosome uptake by recipient cells. 
To visualize the actual internalization of the vesicles and the 
effectiveness of miR-222 transfer from donor into acceptor cells, 
Me1007/miR-222 cells were visualized through the incorporation of 
the fluorescent fatty acid molecule BODIPY® FL C16 (see above 
and the Material and Methods section). Me1007 parental cells and 
Bodipy-labeled EXOs recovered from Me1007/miR-222 cellular 
medium were then incubated for 2 h at 37 °C before confocal 
microscopy evaluation. Control untreated Me1007 and EXO-fused 
cells were stained by phalloidin (Alexa Fluor 647, red) and by the 
nuclear Hoechst dye (blue). The internalization of EXOs was 
evidenced by a green fluorescent punctuate signal inside the 
cytoplasm of Me1007 recipient cells, whereas phalloidin clearly 
defined cell membranes and Hoechst the nuclei (Fig. 16a).  
To quantify the exact number of transferred EXOs, we used a 
Quantum™ MESF (Molecules of Equivalent Soluble Fluorochrome) 
calibration kit to convert fluorescence in a quantum per EXO 
traceable by FACS. In dose/response experiments, control cells were 
incubated with increasing amount of fluo-EXO obtained in control 
and transduced cells and the resulting cell fluorescence evaluated by 
FACS. MiR-222/EXOs were transferred into the acceptor cells with 
similar efficiency of Tween/EXOs. 
To determine the functional effects possibly produced by miR-
222/EXOs and their cargo uptaken by recipient cells,  a series of 
experimental studies was performed. 
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Above all the effectiveness of the horizontal transfer was confirmed 
by specific qRT-PCR for miR-222. Indeed the uptake of miR-222-
containing EXOs by the acceptor melanoma cells produced 3-fold 
increase of miR-222 respect to its basal expression in 
Me1402/R/Tween cells and 1.5-fold respect to the homologous 
control fusion with EXO/Tween (Fig. 16b right). Similar results were 
obtained in Me1007 melanoma cells (2.5-fold increase of miR-222 
respect to its basal cellular expression and 1.3-fold respect to the 
EXO/Tween control (Fig. 16b left). In addition the horizontal 
transfer was confirmed by changes of some other relevant molecules, 
first of all the downregulation of p27Kip1 consequent to EXO/miR-
222 internalization and comparable to that obtained by miR-222 
lentiviral-induced overexpression (Fig. 16c). As suggested by their 
higher expression in EXO/miR-222 respect to EXO/Tween (Fig. 
15a), we observed by western blot the EXO-related capability to 
convey vesicle-markers possibly associated with tumorigenesis, such 











Figure 16. Evaluation of EXOs  uptake by recipient cells. a) Confocal 
microscopy visualization of untreated and EXO/fused Me1007 cell line. 
Me1007/miR-222 were labeled with the fluorescent BODIPY®FL-C16. 
Me1007 recipient cells were stained for phalloidin (Alexa Fluor 647-red) and 
nuclei counterstained with Hoechst. Bodipy C16-labelled EXOs appear as 
internalized green dots. Scale bar: 10 μm. b) The uptake of miR-222-
containing EXOs by the acceptor melanoma cells was quantified by 
specific qRT-PCR (miR-222/RNU6B). Differences in miR-222 expression 
were evaluated using analysis of variance followed by a Newman-Keuls 
post-hoc test. Significance was accepted when the p value was <0.05. c) 
The downregulation of p27Kip1 by EXO/miR-222 was evaluated by WB. 
d) WB analysis after fusion of EXO/Tween or EXO/miR-222 on Tween-
transduced melanomas. MiR-222-transduced cells were included as 
positive control and β-Actin utilized as an internal loading control. 
Figure 16 
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3.5 In vitro functional studies
Basing on these results, we searched for the tumorigenic effects 
associated with EXO/miR-222. Therefore we performed a series of 
biological assays looking for the capability of EXO/miR-222 to 
convey effects similar to those obtained by the direct overexpression 
of miR-222 in melanoma cells. In these experiments, the same 
amounts of EXO/Tween or EXO/miR-222 were incubated with 
recipient cells for 30 min at 37°C before performing expression 
studies and functional assays. Whenever possible, vesicle 
preparations were used immediately after isolation. 
At first and in view of p27Kip1 decrease, we evaluated the cell cycle 
rate possibly modulated as a consequence of EXO/miR-222 
internalization. As already shown for melanoma cells overexpressing 
miR-221 or miR-222, where previous analyses revealed an early 
onset of DNA synthesis paralleled by G0/G1 reduction (Felicetti F., 
2008), we detected an increased proliferative rate in Me1402/R cells 
incubated with EXOs enriched for miR-222. Specifically, 2 h after 
serum stimulation cell cycle evaluation showed either in control 
untreated or in EXO/Tween treated similar distribution: 75–78 % of 
the cells in G0/G1 phase , 7–8 % in S and 14–18 % in G2/M. Values 
were modified by EXO/miR-222 uptake to 62 % G0/G1, 8 % S and 
30 % G2/M confirming the miR-222-dependent increase of 
proliferation  (Felicetti F. De Feo A. 2016) (Fig. 17a). 
We then analyzed the role of EXO/miR-222 on the chemotactic 
capabilities by using a migration and invasion assays. The 
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mechanism underlying these two experiments is the same and 
incorporates the concept of the Boyden chambers where two 
compartments are separated by a porous membrane and the cells pass 
from one compartment to another in response to a chemotactic 
stimulus. In our case cells should be attracted by a serum gradient, as 
it is absent in the upper compartment and 10% concentrated in the 
lower one. The substantial difference is that in the invasion assay the 
membrane is covered with a gelatinous matrix (Matrigel) which 
simulates the extracellular environment and must be proteolytically 
degraded to be crossed. The cells capable of crossing the membrane 
are colored, solubilized and finally quantized by a spectrophotometer 
colorimetric assay. In EXO/miR-222-fused melanoma cell lines we 
observed a small (30% and 50% in Me1007 and Me1402/R 
respectively), but significant induction of the invasion and migration 
capabilities compared to control cells. Possibly due to endogenous 
level of expression of miR-222, we also observed a small increase 
(15%) of chemotactic capability in control cells fused with 
EXO/Tween. MiR-222-transduced cells were always included as a 
positive control (Figs.17b and 17c). 
A specific assay was also performed to evaluate the vessel-like 
process formation, which partly mimics melanoma aggressiveness. In 
particular, after 2 hours of fusion  with EXO/Tween or EXO/miR-
222, melanoma cells were seeded into culture slide wells coated with 
Matrigel growth factor reduced. As shown in Fig. 18 the EXO/miR-
222 fusion clearly enhanced the capability of forming vascular-like 
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structures by Me1007 and Me1402/R. After 24h of incubation, 
EXO/miR-222-fused cells appeared more organized, and joined each 
other as to form vascular-like structures compared to cells fused with 
EXO/Tween.  
Figure 17. Analyses of functional activities of cells  post fusion with 
EXOs. a) Cell cycle analysis, showing the miR-222-dependent early onset 
of DNA synthesis, was performed on synchronized cells 2h after EXO 
internalization. b-c) EXO-dependent effects on invasion (left panels) and 
chemotaxis (right panels) in Me1007 and Me1402/R melanoma cell lines. 
MiR-222-transduced cells were included as a positive control. Data are 
representative of two independent experiments. * p < 0.05; ** p < 0.01. 
a 
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Figure 18. In vitro functional studies in Me1007 and Me1402/R. a) 
Morphological and b) quantitative analyses of tube formation and 
length in Tween- and miR-222-transduced melanoma cells compared 
with EXO/Tween or EXO/miR-222 fused Me1007 or Me1402/R cells. 
Purified EXOs were incubated with recipient cells for 30 min at 37°C 
before performing functional assays. Tube formation was analyzed 20h 
after exosome internalization. Data are representative of three 
independent experiments. * p < 0.05; ** p < 0.01. 
74 
3.6 Activation of the PI3K/AKT pathway by EXO‑miR‑222 
We have recently demonstrated the existence of a cross-regulation 
between the oncomiR-221&222 and the tumor suppressor miR-
126&126*, according to a dynamic balance that during melanoma 
progression moves from miR-126 to miR-221&222 under the 
regulation of the transcription factor AP2α (Felli N., 2015). 
According to this coregulatory circuitry, we observed opposite 
effects of these miRs on some downstream genes, including the 
VEGF, PI3K/AKT signaling pathway that resulted diminished by 
miR-126 and activated by miR-221/-222. Specifically p85β, a 
regulatory subunit of PI3K kinase, reported as a direct target of miR-
126 was significantly repressed in miR-126-transduced melanoma 
cells. Indeed in both melanoma and thyroid carcinoma miR-126 
restored expression was found to act by lowering proliferation and 
AKT kinase activity (Rahman MA., 2015). 
We then evaluated how miR-222-containing EXOs might induce 
their oncogenic program looking for some key molecules involved in 
tumor progression. 
A growing body of evidence has shown that MAPK and PI3K 
signaling play major roles in melanoma development and 
progression (Palmieri G., 2015). In addition the expression of miR-
221 and miR-222 has been reported to be under the positive control 
of the RAS/MAPK (Cardinali B., 2009; Terasawa K., 2009) and 
upstream to PI3K/AKT signaling in different cellular models (Zhang 
J ., 2010; Li W., 2014).   
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Among them, the main components of the AKT/PI3K pathway, 
frequently deregulated in cancer, represent attractive candidates. 
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid enzymes 
divided into three classes (I–III) each with its own substrate 
specificity, structures and lipid products. Class I PI3Ks are 
heterodimers composed of a p110 catalytic subunit (α, β, γ or δ) and 
a p85/p55/p50 regulatory subunit which are activated via tyrosine 
kinase or G protein-coupled receptors. Upon activation, cytosolic 
PI3K is recruited to the plasma membrane where it converts the lipid 
phosphatidyl-inositol bisphosphate (PIP2) to phosphatidyl-inositol 
trisphosphate (PIP3) inducing the colocalization of Akt and the 
phosphoinositide-dependent kinase 1 (PDK1) by their pleckstrin 
homology domain. Akt is then activated through phosphorylation at 
two distinct sites, T308 and S473 (Allegretti M., 2016). As miR-
221&222 deregulation has been associated with these tumorigenic 
pathways and circulating miR-222 was suggested as a possible tumor 
biomarker (Teixeira AL., 2014; Calderaro J., 2014; Lee JC., 2015; 
Chen WX., 2014) expression studies were performed in our cellular 
models. Western Blot showed miR-222-induced upregulation of the 
PI3K/p85β subunit in both melanoma cells and purified EXOs (Fig. 
19a ). The level of p85β appeared doubled in miR-222-transduced 
cells (see densitometric quantification in Fig. 19a), whereas EXOs 
showed a faint miR-222-dependent induction of p85β. In this study 
we then investigated whether the transfer of EXO/miR-222 might be 
sufficient per se to modulate the PI3K/AKT pathway after 
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internalization into the recipient cells. Western blot analysis 
confirmed the increase of PI3K/p85β and ph-AKTSer473, main
molecules involved in this signaling, up to levels similar to those of 
miR-222-transduced cells (Fig. 19b). Results were supported by 
densitometric quantifications and shown as ph-AKTSer
473
/total AKT




Figure 19. WB analysis of proteins modulated by EXO/miR-222 in 
Me1007 and Me1402/R melanomas. a) Western blot analysis of 
PI3K/p85β subunit in Tween control versus miR-222-transduced cells and 
corresponding EXOs (left panel) and relative densitometric quantification 
(right panel). b) Western blot analysis of PI3K/AKT related proteins after 
fusion of either EXO/Tween or EXO/miR-222 on Tween-transduced 
melanomas. β-Actin was utilized as internal loading control. c) 
Quantification of ph-AKT
Ser473
/Akt ratios. Mean ±SD of three 
independent experiments. * p < 0.05. 
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3.7 Effects of miR-222 overexpression on PI3K/AKT axis 
inhibition. 
To assess the possible differential significance of PI3K blockade in 
control vs miR-222-transduced cell lines, we treated either 
synchronized or not synchronized melanoma cells with NVP-
BKM120, a potent class I PI3K pure pan inhibitor, at doses ranging 
between 2.5 and 5 μM. Results were evaluated on cell cycle rates. 
In both treatments, miR-222 overexpression seemed to interfere with 
BKM120-dependent effects. In hydroxyurea (HU) synchronized 
cells, 2 h after medium replacement, cell cycle determination showed 
the miR-222-dependent earlier onset of DNA synthesis in both 
untreated and BKM120-treated Me1007/miR-222 compared with 
control vector transduced cells (Fig. 20a). When the effects of 
BKM120 were evaluated on not synchronized proliferating 
melanoma cells, miR-222 seemed to interfere with the BKM120-
dependent block in the G2/M phase (Fig. 20c). Western blot analyses 
and densitometric quantitations confirmed ph-AKTSer
473
, CycD1
and PI3K/p85β downregulation (Figs 20b and d). The capability of 
miR-222 to partially counteract the selective inhibition of PI3K/AKT 
pathway could be explained on one side considering the frequent 
constitutive activation of the MAPK axis, often functional to 
melanoma, on the other taking in mind the high number of genes 
targeted by each miR.  
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 Figure 20. Effects of miR-222 
overexpression on the inhibition 
of PI3K/AKT axis. Cell cycle 
analysis of miR-222-transduced vs 
control cells treated with 2.5 and 5 
µM of BKM120 in a) synchronized 
Me1007 and c) proliferating
Me1402/R. b) and d) Relative 
densitometric quantification of WB 
performed in the same cells. β-Actin 
was utilized as internal loading 
control. Data are representative of 
two independent experiments. * p < 
0.05; ** p < 0.01. 
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3.8 Effects of antagomir-221&222 carried by exosomes. 
The functional effects of EXOs recovered from melanoma cells after 
miR-222 inhibition were also analyzed. The endogenous miR-221 
and miR-222 expression were reduced by transfecting antagomirs, 
chemically modified oligomers complementary to mature miRs 
(Felicetti F., 2008). As a control, we used an unrelated antagomir, 
specifically the antagomir targeting miR-133a (αmiR-133) that we 
found not expressed in our melanoma cell lines. EXOs were purified 
from conditioned media 24 h after transfections. The choice of 
abrogating both miRs derive from their possible redundant roles 
based on the high number of shared target genes (Felicetti F., 2008). 
Previous studies showed reduced cell proliferation and decreased 
invasion and migration abilities in melanoma cell lines transfected 
with these highly stable oligomers (Felicetti F., 2008). Accordingly, 
we observed by Western Blot the antago-dependent reduction of the 
PI3K/AKT/CycD1 axis, together with the upregulation of p27Kip1 
(Fig. 21a). In line with miR-221&222 abrogation, the antagomir-
carrying EXOs were able to reduce the cell cycle rate of melanoma 
acceptor cells blocking the EXO/αmiR-221&222-treated cells in the 
G0/G1 phase (EXO/αmiR- 221&222 treatment: 82 % of the cells in 
G0/G1, 17 % in S, 1 % in G2/M vs control or EXO/Tween treatment: 
57–62 % in G0/G1, 34–39 % in S, 4 % in G2/M) (Fig. 21b). Yet 
again more evident differences were detected in the formation of 
vascular-like structures resulting reduced and less organized by the 
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α-miR-221&222/EXO internalization after 20 hours and 2 days (Fig. 
21c). In line with these functional effects, we detected the regulation 
of some key factors involved in cell growth, apoptosis and tube 
formation. qRT-PCR  assays showed  reduced levels of Bcl2, ITGβ3, 
FGF2 and VEGF (Fig. 21d). The specificity of miR-222 down-
regulation was confirmed by qRT-PCR in α-221&222/EXO (Fig. 





Figure 21. Effects on melanoma tumorigenesis of antagomir-
221&222 carried by EXOs. Melanoma cells treated with control 
antagomir-133 (αmiR-133)- or antagomiR-221&222 (αmiR-221+222)-
EXOs were compared for a) modulation of protein expression by 
Western blot, b) cell cycle rate, c) tube-like formation capability 
evaluated at 20h and 2 days after EXO internalization. qRT-PCR 
evaluation of d) miR-222 related molecules and e) miR-222 itself to 
confirm its inhibition. Relative miR expression levels were normalized 
on RNU6B. Data are representative of two independent experiments. * 
p < 0.05; ** p < 0.01. β-Actin and GAPDH were utilized as internal 
controls. 
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3.9 Analysis of “Human tumor metastasis genes” in EXO/Tween 
vs EXO/miR-222. 
To further dissect the role of miR-222 in the EXO cargo of 
Me1402/R melanoma, we compared the expression profiles of 
EXO/Tween and EXO/miR-222 by using the TaqMan array plate for 
Human tumor metastasis genes (Fig. 22a).  
As possibly expected in view of the low amounts of RNA recovered 
from EXOs, qRT-PCR analyses revealed that the majority of genes 
exhibited Ct values higher than 35. Even so, in agreement with miR-
222 tumor promoting function, we observed the up-regulation of a 
number of genes involved in melanoma progression. Among them 
we found the miR-222-based upregulation of VEGF and FGF2 well 
known to play major roles in melanoma cell growth and tumor 
angiogenesis according to autocrine and paracrine functions 
(Halaban R., 1996; Mahabeleshwar GH., 2007). Interestingly, some 
other factors, as the MGAT5, MCAM and TGFβ1, cooperating in the 
induction of prometastatic phenotypes in melanoma (Bubka M., 
2014; Mendelsohn R., 2007), were induced by miR-222. Finally, 
among the few genes downregulated in EXO/miR-222, we detected 
MTA1 and MTA2, nuclear receptor coregulators overexpressed in 
human cancers, but reported to play a dual role being either 
corepressors or coactivators (Li DQ., 2012). The accuracy of these 
microarray results was validated by qRT-PCR of FGF2 and VEGF 
genes. (Fig.22b) (Felicetti F. De Feo A., 2016). 
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Figure 22. Expression profiling of the exosomal cargo. a) Differentially 
expressed genes obtained by the TaqMan Array Plate for Human Tumor 
Metastasis genes in EXO/miR-222 vs EXO/Tween samples. b) The 
expression level of some selected genes modulated in TaqMan Array Plate 
was confirmed by qRT–PCR.  
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3.10 CD99, miR-34a and Ewing’s sarcoma. 
Major advances in molecular genetics over the last few years have 
made possible to identify CD99, a molecule governing many key 
components of the metastatic process. This cell surface molecule was 
indeed reported to influence: a) adhesion among tumor cells as well 
as to extracellular matrix (ECM) components (Husak Z., 2012; 
Scotlandi K., 2007); b) endothelium extravasation (Dufour EM., 
2008); c) cell capabilities to survive, proliferate, differentiate and 
respond to stress (Cerisano V., 2004; Rocchi A., 2010) ; d) 
communication between cancer cells and tumor microenvironment 
via molecular interactions (Scotlandi K., 2007; Edlund K., 2012 ; 
Manara MC., 2006). Considering that CD99 is also involved in the 
regulation of intracellular membrane protein trafficking (Bremond 
A., 2009; Sohn HW., 2001) as well as of several signaling pathways 
that control the synthesis of proteins (MAPK, AKT/mTOR signaling 
pathways) (Byun HJ., 2006), it is plausible that this molecule acts as 
a master regulator of “how and when” specific proteins can be 
translated and delivered to specialized compartments in the cells. For 
all these reasons, CD99 may represent an attractive therapeutic target 
in cancer treatments. 
Data obtained in Dr. Scotlandi’s lab demonstrated that CD99 
contributes to cell proliferation, migration, and metastasis of EWS 
cells and inhibits their neural differentiation (Fig. 23) (Rocchi A., 
2010; Ventura S., 2015). Cells with reduced expression of CD99 
showed a concomitant reduction of growth and cell motility, 
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additionally, displaying increased adhesion to extracellular matrix 
components, including collagen I and IV. The reexpression of CD99 
in silenced clones completely rescued growth and migratory 
capacities to the same levels as in the parental cell lines (Ventura S., 
2015). Accordingly the introduction of a CD99-shRNA construct 
induced a phenotype consistent with neural differentiation (Fig. 23). 
Reduction of CD99 expression resulted in neurite outgrowth and 
increased expression of β-III tubulin and H-neurofilament (H-NF), a 
late and very specific marker of neuronal differentiation. In vivo 
experiments into immunodeficient mice have pointed out how CD99 
knockdown significantly revert the malignancy of EWS and inhibit 
its metastatic potential (Rocchi A., 2010; Guerzoni C., 2015).  
Recent data demonstrated that NF-kB was heterogeneously 
expressed in a panel of ES cell lines. In these cells, stable CD99 
silencing decreased the transcriptional activity of NF-kB. 
Specifically, CD99 did not regulate NF-κB either at mRNA or 
protein levels, but rather indirectly through its signaling machinery 
(Ventura S., 2015). 
Studying the mechanisms involved in transcriptional regulation of 
NF-kB, Ventura and coauthors investigated the role of Notch 
signaling, a developmental pathway involved in the regulation of cell 
fate, previously included in a reciprocal NF-kB↔Notch regulatory 
model in other specific cellular contexts (such as during T-cell, 
neuron and osteoblast differentiation, and in pancreatic cancer cells 
(Wang Z., 2006; Wang Z., 2006) . They demonstrated that Notch 
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inhibition was associated with the NF-κB-mediated neural 
differentiation of EWS cells with miR-34a representing the molecule 
bridging CD99 with Notch and NF-κB. Exposure of EWS cells to 
miR-34a mimic decreased the expression of Notch1 and the 
transcriptional activity of NF-κB, in turn increasing neural 
differentiation. These data indicated that the capability of the sole 
miR-34a to reproduce all the CD99-shRNA effects on EWS cell 
differentiation, thus correlating with a good prognosis. Indeed its 
over-expression in EWS cell lines, besides resulting in a reduction of 
proliferative potential and cell malignancy, induced a greater 
sensitivity to classic chemotherapy agents used in the therapy of 





Figure 23. Analyses of functional activities of EWS cells silenced for CD99. a) 
Cell proliferation rate (left panel), capability of forming foci in agar semisolid 
medium (middle panel) and migration assays ( right panel). b) Expression levels of 
CD99 and  miR-34a evaluated by WB or qRT-PCR in TC71-CD99-shRNA and in 
control cells. c) Evaluation of H-NF and β-III tubulin expressions by 
immunofluorescence.  
89 
3.11 Characterization of exosomes released by Ewing’s sarcoma 
cell lines. 
In view of the tumorigenic role played by CD99 in EWS, we 
evaluated the presence or absence of CD99 in EXOs released in 
culture media by different EWS cells. EXOs were then purified by 
UC or EQ methods from conditioned media of either parental or 
CD99-shRNA EWS cell lines. As experimental models we selected 
the TC-71 and IOR/CAR cells in view of their capability to 
differentiate. 
The protein content of the CD99-shRNA-derived exosomal cargo 
analyzed by western blot, besides showing the expected lack of 
CD99, evidenced the enrichment of proteins commonly used as 
microvesicle markers, such as RAB5B, CD63 and CD81 (Fig. 24a). 
According to null expression of CD99 in EXOs derived from CD99-
shRNA cells and in line with miR-34a downregulation in EWS 
(Marino M.T., 2014), we also investigated the EXO-associated 
expression levels of miR-34a. MiR-34a was already described in 
EXOs derived from different tumors, including breast, prostate and 
brain (Zhang J., 2015; Corcoran C., 2014; Sarkar S., 2016). 
Accordingly, by qRT-PCR we found miR-34a in EWS EXOs. 
Specifically we detected higher amounts of miR-34a in EXO-
shCD99 than in EXO-shCTR (Fig. 24b), thus indicating a 
hypothetical cross talk between miR-34a and CD99 at the level of 
vesicular trafficking. MiR-16 was used as internal standard, because 
it resulted relatively invariant across our EWS cell lines. 
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3.12 Downregulation of the Notch pathway in sh-CD99/EXOs. 
In view of the down modulation of the Notch pathway in CD99-
shRNA EWS cell lines, we analyzed the expression of some relevant 
molecules involved in this via in EXOs deprived of CD99 and in the 
corresponding parental EXOs. 
By Western Blot we observed, either in CD99-shRNA EXO TC-71 
or IOR/CAR models, a significant repression of Notch 1 and Notch 
3, transmembrane receptors that, mediating cell-to-cell 
communications, regulate cell fate decisions during developmental 
stages as well as adult life (Fig. 24c). Notch downregulation was 
coincident with higher expression of miR-34a. α-Tubulin was used as 
internal EXO control. 
3.13 Different effects induced into recipient cells after fusion with 
EXOs±CD99. 
We then evaluated whether the uptake of EXOs from CD99-silenced 
cells by parental EWS cells might be sufficient to mimic CD99 
silencing in virtue of miR-34a content. We performed an in vitro 
experimental model of fusion with the same amounts of EXOs either 
purified from parental or CD99-shRNA EWS cell lines. EXOs were 
incubated with recipient cells for 24 h at 37°C before performing 
expression studies and functional assays. Evidence of effective EXOs 
internalization was indirectly obtained by revealing CD99 expression 
variation in CD99-shRNA cells after exposure to EXOs derived from 
parental and silenced cells (Fig. 24d). Western Blot analyses showed 
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that CD99 silenced cells, once in contact with the wild type EXOs 
purified from control cells, reexpressed this membrane protein. 
Furthermore, the expression level of CD99 in CD99-silenced cells 
was further reduced by the uptake of shCD99-EXOs produced by 
these same cells (Fig. 24d). More important, EXOs released by 
CD99-silenced EWS cells have the capacity to interfere with the fate 
of human EWS cells. In sarcoma recipient parental cells, EXOs 
devoid of CD99 can indeed induce cell differentiation toward a 





After immunofluorescence staining, by confocal visualization we 
observed positive signals for the differentiation marker βIII tubulin 
and the filament of heavy chains H-NF, thus confirming that fusion 
with EXOs/CD99-shRNA induced neural differentiation in TC-71 
and IOR/CAR parental cells. Indeed we also observed the reverse 
effect when internalization of EXOs derived from parental cells 
Figure 24. Characterization of EWS EXOs. a) Representative 
Western Blot showing CD99, RAB5B, CD63 and CD81 in EXOs 
of TC-CD99-shRNA and CAR-CD99-shRNA experimental 
models. b) Exosomal miR-34a expression is shown for TC-71, 
TC-CD99-shRNA #2 cells and IOR/CAR, CAR-CD99-shRNA #1 
cells. Results are referred to miR-16 as a constantly expressed 
internal standard (mean±s.e.m. of two independent experiments; 
*P<0.05 Student’st-test). c) Exosomal protein expression was
detected by western blot. Blots of Notch 1 and Notch 3 are 
representative of three independent experiments. α-Tubulin was 
used as a loading control. d) CD99 expression variation in CD99-
shRNA cells after exposure to exosomes derived from parental and 
silenced cells . 
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abrogated the differentiated phenotype of CD99-shRNA cells (Fig. 
25).
F
Figure 25. Neural 
differentiation. 
EXOs released by 
CD99-silenced EWS 




staining of β-III 





Scale bars: 50 μm. 
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3.14 EXOs ± CD99 modulate the transcriptional activity of NF-
kB. 
Deprivation of CD99 drives EWS cells toward neural differentiation. 
Looking for the underlying molecular mechanisms, we observed a 
significant downregulation of NF-κB activity upon CD99 silencing. 
In general, the activation of NF-κB occurs when NF-κB members are 
transported from the cytoplasm to the nucleus uncoupling NF-κB 
factors from inhibitory IκB proteins. Optimal induction of NF-κB-
target genes also requires phosphorylation of NF-κB proteins, such 
as p65, whose phosphorylation at Ser536 enhances its transactivation 
potential. Accordingly, knockdown of CD99 reduced the levels of 
Ser536 phosphorylation in EWS cells .  
In order to identify transcription factors possible modulated after the 
uptake of TC-71- or TC-CD99shRNA-EXOs by the recipient cells, 
we used a luciferase reporter gene assay. This technique allows 
assessing the transcriptional activity of cells transfected with a 
reporter construct containing the luciferase gene under the control of 
the promoter of interest. After 24h of transfection, the same amounts 
of control or CD99 null purified EXOs were incubated with recipient 
cells for 30 minutes at 37 °C before evaluating luciferase activity. 
The luciferase enzyme eventually expressed catalyzes the oxidative 
carboxylation of luciferin to produce luminescence. This effect can 
be quantified with a luminometer and the amount of photons detected 
correlates directly with the binding activity of the transcription factor 
under study.  
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In our experimental model we analyzed the transcriptional activity of 
NF-kBp65, given its implication not only in inflammation and 
apoptosis, but also in differentiation processes, here specifically in 
neural differentiation. Fusion with sh-CD99-EXOs downregulated 
NF-kB activity in ES cells, more strongly in the IOR/CAR model 
(Fig. 26). 
In both the analyzed experimental models, TC71 and IOR/CAR NF-
kBp65 is significantly down-regulated after fusion  with  sh-CD99-
EXOs suggesting that the compositions of EXOs from cells deprived 
of CD99 is therefore sufficient  to induce the same phenotype 
obtained by stable CD99 silencing in recipient parental cells. In 
conclusion, confirming the sequential pathway 
miR34a→Notch→/NF-kB that follows CD99 silencing, our results 
suggest that EXOs released from CD99–silenced EWS cells have the 
capacity to interfere with the fate of human EWS cells. 
Figure 26. NF-κB transcriptional activity. Analysis of TC-71, 
IOR/CAR and CD99-shRNA clones after fusion with CD99-shRNA-
derived EXOs (data indicate mean ± s.e.m. of two experiments performed 
in triplicate. *P<0.05 Student’s t-test). Percentages of β-III Tubulin-




Vesicle shedding from live cells was ﬁrst observed in the early 1980s 
when was proposed to be a mechanism used by the cells just to 
discard their garbage. It was only in 1996 that Raposo and his 
coauthors used this definition to describe the secretion of MHC class 
II-containing vesicles and their ability to stimulate T cells (Raposo 
G., 1996). Since then growing attention has focused on the active 
roles of these small membrane vesicles and it is now widely accepted 
their key role in cell-cell communication.  
Intercellular communication is a complex process responsible for 
maintaining normal tissue homeostasis, but also playing a central 
role in cancer initiation and progression. Several reports documented 
that such intercellular communications were modulated by various 
humoral factors, as growth factors, cytokines and chemokines and, 
according to more recent advances, also by extracellular vesicles 
(EVs). EVs have a heterogenetic population and are generally 
categorized as exosomes (EXOs), ectosomes or microvesicles and 
apoptotic bodies. These different types of vesicles can be 
distinguished on the basis of their origin, size, morphology and 
composition (Nawaz M., 2014; Raposo G., 2013; Fujita Y., 2016). In 
particular, EXOs are nanovesicles of diameter ranging between 50 to 
140 nm and, according to their endosomal origin, enriched of certain 
proteins, including members of the tetraspanin family (CD9, CD81, 
CD63), heat shock proteins (HSP60, HSP70, HSP90), membrane 
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transporters and fusion proteins (Annexins, flotillin, RabGTPases) 
and MVB synthesis proteins (Alix and TSG101) (Figs 1 and 12). 
Well defined protocols have been proposed for EXOs selection. 
Nonetheless, as still no general consensus exists on the various 
technical approaches, we started our studies utilizing and comparing 
ultracentrifugation (UC) and the commercial Polymer-based 
precipitation system ExoQuick™ TC (EQ) as alternative methods to 
isolate EXOs (Fig. 12). Purified EXOs, either released by melanoma 
or by Ewing’s sarcoma cells, were analyzed by western blot and/or 
NanoSight technologies, the latter being an easy to use reproducible 
platform for nanoparticle characterization. Results obtained through 
both purification methods showed the correct size of these vesicles as 
well as the enrichment for some vesicular proteins, as LAMP2, 
CD63, CD81, RAB5B, TSG101, HSP90 and β-ACTIN (Figs 15b, 
15c and 24). 
According to functional studies, a number of evidences has shown 
the functional involvement of EXOs in all the main biological 
processes, including cancer development and progression, where 
they can act either as oncogenes or tumor suppressors (Squadrito 
ML., 2014). Specifically, EXOs secreted by tumor cells are shown to 
transfer their oncogenic activity via horizontal propagation of 
functional cellular components such as proteins, lipids, mRNAs and 
miRs. This class of post-transcriptional gene expression regulators is 
known to play critical roles and, among many other diseases, its 
98 
dysregulation has been associated with cancer development and 
progression. In addition miRs display specific expression proﬁles in 
normal tissues and cancers (Garzon R., 2010) and their different 
levels can be easily evaluated in human body fluids. One important 
breakthrough was the detection of miRs in EXOs (Valadi H., 2007) 
and the capability demonstrated by recipient cells to uptake and 
utilize the exosome contained cargos (Valadi H., 2007; Ohshima K., 
2010). 
Several studies have analyzed the function and transfer of secretory 
miRs contained inside the EXOs. A good example was that reported 
by Le et al. showing the ability of highly metastatic breast cancer 
cells to transfer their aggressiveness to the non-metastatic ones 
through EV-containing members of the miR-200 family. Transfer of 
miR-200 induced the epithelial-mesenchymal transition (EMT) by 
altering the expression of genes, including zeb2 and sec23a, in 
poorly -metastatic breast cancer cell lines (Le MT., 2014). 
Based on our previous studies demonstrating the active role played 
by miR-221&222 on tumor proliferation and progression (Felicetti 
F., 2008; Errico MC., 2013), we focused this study on miR-222 
showing that it is part of melanoma exosomal cargo and can be 
transferred between cells resulting per se able to promote 
tumorigenesis through the activation of several molecules, including 
the PI3K/AKT pathway. In particular, we evidenced that miR-222 
exosomal expression mostly reflected its abundance in the cells of 
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origins thus confirming its gradual increase associated with 
melanoma progression. Accordingly, a significant accumulation of 
this miR was detectable in EXOs purified from primary melanoma 
cell lines (Me1007 and Me1402/R) enforced to express miR-222 
(Fig.15a) by lentiviral gene transduction. Indeed the mature sequence 
of miR-222 contains two short sequence motifs reported to function 
as packaging signals that control the loading of these miRs into 
EXOs (Villarroya-Beltri C., 2013). 
Utilizing proper experimental models, we demonstrated that 
melanoma cells can transfer their oncogenic properties via EXOs. 
We got higher invasive and chemotactic capabilities and, even more 
evident, vessel-like process formation associated with EXO/miR-222 
internalization into primary melanomas, indicating increased 
melanoma malignancy (Figs. 17 and 18) (Yazawa EM., 2015) . The 
reverse effects obtained after internalization of EXOs released by 
antagomir-transfected cells (αmir-221&222) supported our 
conclusions (Fig. 21).  
Trying to dissect the downstream pathways regulated by miR-222, 
we demonstrated, either in melanoma cells or secreted EXOs, the 
miR-222-dependent induction of the PI3K/AKT pathway, associated 
with the expected downregulation of p27Kip1 direct target of miR-
222. As no significant differences were detected in the cell-cycle 
rates of miR-222-overexpressing cells treated or not with the AKT 
inhibitor BKM120 (Fig. 20), we faced the capability of miR-222 to 
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overcome the inhibition of the PI3K/AKT pathway. One explanation 
could be the frequent constitutive activation of the MAPK axis in 
melanoma,, but also the high number of genes directly targeted by 
miR-222 inhibiting proliferation, inducing apoptosis or generally 
playing tumor suppressor functions, should be considered (Garofalo 
M., 2012). 
According to the reported association between the number of 
released EXOs and tumor malignancy (Peinado H., 2012), miR-222 
seemed also to augment the amount of secreted EXOs per cell. In 
agreement with their functional roles recently associated with cancer, 
some exosomal markers resulted upregulated by miR-222 (Fig. 15). 
Among them, RAB GTPases were implicated in membrane 
trafficking and EXO secretion in melanoma. Specifically RAB5B 
and RAB27 were shown to increase the release and transfer 
capability of the microvesicles being involved in tumor 
metastatization including melanoma (Peinado H., 2012; Ostrowski 
M., 2010, Boelens MC., 2014; Raposo G., 2013). Also the 
tetraspanin CD63, a well-known marker of microvesicles, was 
associated with prometastatic pathways (Seubert B., 2012) and 
evidenced together with CAV-1 on plasma EXOs of melanoma 
patients (Logozzi M., 2009). Previous studies linked CAV-1 
overexpression with melanoma malignancy showing that its secreted 
amounts loaded in the exosomal cargo were involved in cell 
migration (Felicetti F., 2009; Diaz J., 2014). Indeed, recent studies 
supported the notion of the pro-metastatic role of CD63 through β-
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catenin induction and subsequent increase of ERK phosphorylation 
and PI3K/AKT pathway activity (Seubert B., 2015;  Toricelli M., 
2013; Cui H., 2015). Although these increases might suggest the 
involvement of miR-222 in the EXO releasing process, at present no 
significant data directly correlate these exosomal markers with miR-
222. 
The expression profiles obtained by analyzing a panel of tumor 
metastasis genes further demonstrated the presence of higher levels 
of tumor promoting genes in EXO/miR-222. Among them we found 
MGAT5, which in melanoma plays a role during the transition from 
the vertical growth phase to the metastatic stage, together with its 
targets MCAM (Bubka M., 2014), and TGFβ expressed in most 
malignant melanomas and correlating with poor survival (Tang MR., 
2015). Last but not least the increased levels of the growth factors 
VEGF and FGF2 found into the exosome cargo (Fig. 22), besides 
underlying the miR-222 induction of vascular-like structures, 
suggested the exosome-based transport to explain the unconventional 
leaderless secretion of FGF2 (Fig. 27). 
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Figure 27 
Figure 27. Schematic illustration of pathways regulated by 
EXO/miR-222 in melanoma. 
As already mentioned, EXOs contain functional cellular components 
such as proteins, mRNAs, and miRs that enable the transfer of these 
principal factors to various cell types (Saleem SN., 2015). These 
components are functional in the recipient cells and are highly 
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variable depending on the origin cells. Looking for a second cellular 
model, we analyzed the role of EXOs derived from Ewing’s sarcoma 
cells. In particular we evaluated the different properties of EXOs 
devoid or not of CD99, a key protein involved in oncogenesis and 
cellular differentiation of EWS, together with the well-known fusion 
protein EWS-FLI1. These two proteins are reciprocally regulated, as 
CD99 facilitates the EWS-FLI1 oncogenic activity is by, and EWS-
FLI1 maintains high levels of CD99 expression through direct 
binding to its promoter or indirectly through miRNA regulation. 
Dr. Ventura and colleagues showed in EWS cells that, as a 
consequence of CD99 deprivation, Notch1 and 3 are reduced and that 
miR-34a plays a central role in this pathway being upregulated in 
CD99-silenced cells. According to multiple cross-talk mechanisms 
described between Notch and NF-κB, miR-34a mimic reduces 
Notch1 and NF-κB increasing neural differentiation of EWS cells 
(Fig. 23) (Ventura S., 2015). 
As the EXO contents specifically derive from their releasing cells, 
we performed our experiments exposing EWS parental cells to EXOs 
derived from cells silenced for CD99. Interestingly, these 
siCD99/EXOs showed a higher content in miR-34 and their delivery 
to parental EWS cells induced a repression of Notch1 and 3 
expression as well as of NF-KB transcriptional activity thus once 
again confirming the great power of EXO-mediated diffusion in this 
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case based on CD99 abrogation and/or miR-34 induction (Figs. 24, 
25 and 26). 
Figure 28 
Figure 28. Schematic representation of the mechanistic 
relationship between CD99-silencing and EWS neural 
differentiation. 
Actually, different experimental data suggest that miR-34 family, 
playing tumor suppressive effects, might have diagnostic and 
prognostic potential and can be predictive of therapy responses in 
different tumor types. Results produced by Dr. Scotlandi’s lab have 
shown that miR-34a expression is a strong predictor of outcome in 
EWS, as patients with the highest expression of miR-34a did not 
experience adverse events in five years (Nakatani F., 2012; Marino 
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M., 2014), likely because increased chemosensitivity of cells to 
conventional agents (Nakatani F., 2012; Rocchi A., 2010; Ventura S., 
2015). The capacity to interfere with the fate of human EWS cells of 
EXOs released from CD99-deprived EWS cells, possibly in view of 
miR-34 efficacy, opens new important avenues for therapy. 
Actually, small RNAs, including siRNAs and miRs, are already 
opening a new avenue for the treatment of various diseases. 
Understanding the precise mechanisms of EXOs in cancer biology 
may provide a breakthrough in the diagnostic and prognostic tools 
and therapeutic strategies of cancer. Because of their biological 
nature, EXOs have considerable advantages, including direct 
cytosolic delivery without causing genomic insertion or 
inflammatory response, over other biomaterials such as viruses and 
synthetic nanoparticles. Despite advances in exosomal therapy, there 
are still many challenges to be properly face. The first obstacle is the 
question of achieving the large-scale production of EXOs for clinical 
use. Although the oncogenic immortalization of human stem cells 
represents a robust source for manufacturing therapeutic EXOs, this 
technique involves using an oncogenic lentivirus, which nullifies the 
premise of using EXOs instead of viruses for gene therapy (Chen 
TS., 2011). Moreover, small RNA loading and EXO isolation are 
expensive and labor-intensive. Second, a robust cell source that 
produces high quantities of EXOs is not established. Because the use 
of cell types from a heterologous source to produce EXOs may cause 
ethical and histocompatibility problems, the use of patients’ own 
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cells is optimal. However, which human cell type to use for EXO 
derivation remains unsettled. In addition, to extend the tissue-specific 
delivery technology, new targeting peptides, ligands, and antibody 
fragments linked to exosomal surface proteins should be developed. 
Finally, as injected EXOs are mainly eliminated in liver and kidney, 
it requires further examination whether EXOs may disrupt the 
physiological status or impair the function of these organs, 
particularly because the EXO-dependent effects are not permanent 
and patients require continuous administration.  
All together EXO-based transfer of miRs represent a powerful tool in 
tumor treatment not only because of intrinsic efficiency of EXOs in 
intercellular communication, but also for the miR-dependent cascade 
effect due to the simultaneous modulation of multiple genes. In 
addition, miRs might be considered the most effective fraction in the 
exosomal cargos in view of their stability, broad  and direct 
functional activity.  
To date miR-221&222 and miR-34 are among the most characterized 
microRNAs in a variety of tumors where they act as oncomirs or 
tumor suppressor, respectively. Hence the abrogation of the former 
by EXO vehicled antisense sequences and the enforced expression of 
the latter by reintroducing miR-34 mimics represents a novel tool to 
combat metastasis, chemoresistance and tumor recurrence. Also 
important synergistic effects have been obtained by simultaneous 
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delivery of chemotherapeutic drugs and miRs co-loaded into EXOs 
(Shi S., 2014; Deng X., 2014). 
The growing understanding of cancer cell-derived vesicles, of EXO-
mediated uptake and transfer of the molecular cargos is making more 
realistic to easily evaluate EXOs in plasma from patients. Our results 
implicate miR-222 and miR-34a, either cell-associated or EXO-
transported, as positive and negative regulators of tumor malignancy, 
supporting their potential validity as diagnostic and prognostic 
biomarkers well as promising therapeutic options. In a not too far 
future it will be possible to use EXOs for modulating target genes for 
therapeutic purposes, but a great deal of additional research will be 
required to develop these therapies for clinical use. The development 
of ad hoc procedures will definitely allow the transition from bench 
to bedside . 
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5. MATERIALS AND METHODS
5.1 Cell culture 
Human melanoma cell lines were stabilized from surgical specimens 
obtained from primary or metastatic tumors at Istituto Nazionale 
Tumori (Milan, Italy). Cell lines were characterized for growth in 
soft agar and, whenever possible, their metastatic potential was 
evaluated into athymic nude mice. Early passages cells were 
obtained from bioptic specimens at Istituto Dermopatico 
dell’Immacolata (Rome, Italy). All biological materials were 
obtained with the informed consent of patients and the study was 
conducted according to the Declaration of Helsinki Principles. The 
cell lines were authenticated according to standard short tandem 
repeat (STR)-based genotyping. Melanoma cell lines were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO by Life 
Technologies, Paisley, UK) supplemented with 10 % FBS (GIBCO). 
Cells were incubated at 37 °C and supplemented with 5 % CO2 in 
humidified chamber. Treatments with NVP-BKM120 (Selleckchem, 
Houston, TX, USA), a PI3K specific pan inhibitor, were performed 
at doses ranging between 2.5 and 5 μM in synchronized or not 
synchronized melanoma cells, in presence of 5 or 10 % FBS 
previously deprived of endogenous microvesicles by 
ultracentrifugation. 
TC-71 and IOR/CAR EWS cell lines were a generous gift from Dr. 
Scotlandi at the Istituti Ortopedici Rizzoli (Bologna, Italy). Cells 
were routinely cultured in IMDM (Life Technologies, Inc., Paisley, 
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UK), and 10% FBS (Biological Industries, Kibbutz Beth Haemek, 
Israel). Cells were maintained at 37°C in a humidified 5% CO2 
atmosphere. 
5.2 Silencing of CD99 by transfection. 
For stable silencing of CD99, an shRNA plasmid (pSilencer 2.1-U6 
Neo vector; Ambion, Grand Island, NY) expressing CD99 siRNA-1 
(5′ GATCCGGCTGGCCATTATTAAGTCTTCAAGAG 
AGACTTAATAATGGCCAGCCTTTTTGGAAA-3′) was 
synthesized, and EWS cells were transfected using the calcium 
phosphate method (Calcium Phosphate Transfection Systems kit, 
Invitrogen, Grand Island, NY, USA). Stable transfectants expressing 
shRNA-CD99 or negative controls TC-CTR-shRNA were obtained 
after selection in neomycin (500 μg/ml) (Sigma-Aldrich, St Louis, 
MO, USA) (Rocchi A., 2010). In analogous the same constructs were 
obtained in IOR CAR models. In this case CAR-CTR-shRNA and 
CAR-CD99-shRNA clones were selected in complete medium 
supplemented with 1000 μg/ml neomycin (Ventura S., 2015). 
5.3 Transduction of miR-222. 
Lentiviral vector222 precursors cDNA was PCRamplified from a 
human BAC clone by using AccuPrimeTaq DNA polymerase high 
fidelity (Invitrogen, Grand Island, NY, USA). MiR-222 was first 
cloned in the pCR 2.1-TOPO vector (Invitrogen, Grand Island, NY, 
USA). Thereafter, they were inserted under CMV promoter into a 
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variant third-generation lentiviral vector, pRRL-CMV-PGKGFP-
WPRE, called Tween, to simultaneously transduce both the reporter 
GFP and the miR in melanoma cells. The primers for miR-
222amplification were: DIR 5'-TCATCATTCATAAAACCTTG-3', 
and REV 5'-TACGTACATGGGAATATTGT-3'. All sequences were 
confirmed by automated sequencing (Kimmel Cancer Institute, 
Thomas Jefferson University). 
5.4 MiR‑221 and miR‑222 silencing by antagomir treatment. 
Chemically modified antisense oligonucleotides (antagomir or αmiR) 
were used to inhibit miR expression (Felicetti F., 2008) . The 
sequences of αmiR-221 and αmiR-222 used are: 5′P  
GAAACCCAGCAGACAAUGUAGCU-3′-Chl and 5′P-
GAGACCCAGUAGCCAGAUGUAGCU-3′-Chl, respectively; all 
the bases were 2′OMe modified. Antagomir oligonucleotides, were 
transfected at 200 nmol/L by using Lipofectamine 2000 (Invitrogen 
Grand Island, NY, USA), according to the manufacturer’s 
procedures. As a control, we used an unrelated antagomir 
(specifically the antagomir targeting miR-133a (αmiR-133), that is 
not expressed in our melanoma cell lines. EXOs were purified from 
conditioned media 24 h after transfections. 
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5.5 Exosome isolation and tracking analysis. 
EXOs were isolated from 24 h cell culture media by 
ultracentrifugation (UC) or Exoquick-TC (EQ) (System Biosciences, 
Mountain View, CA) methods according to standards procedures or 
manufacturer’s instruction, with minor modifications (Fig. 12a). For 
cell culture media utilized in exosome purification, serum was 
depleted of bovine EXOs by ultracentrifugation at 100,000×g for 6 h, 
followed by passing it through 0.2 μm filter prior to use. The protein 
concentration of EXOs was determined using a protein assay kit 
(Bio-Rad, Hercules, CA) and in some cases the number and size of 
EXOs were directly tracked using the Nanosight NS300 system 
(Nanosight™ technology, Malvern, UK), configured with a 488 nm 
laser and a high-sensitivity sCMOS camera. Videos were collected 
and analyzed using the NTA software (version3.0). For each sample, 
multiple videos of 60 s duration were recorded generating replicate 
histograms that were averaged. 
5.6 Exosome labeling and internalization. 
Melanoma cells were labeled by including into the culture medium 
(DMEM supplemented with 0.3 % FBS-UC) the Green fluorescent 
fatty acid molecule BODIPY® FL C16.(4,4-difl uoro-5,7 dimethyl-
4-bora-3a,4a-diaza-s-indacene-3-hexadecanoicacid) (C16).  
After 5 h of incubation, the dye in excess was washed out and cell 
culture media containing EXOs, with fluorescent phospholipids 
incorporated into membranes, were recovered. Thirty micrograms of 
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EXOs (purified with EQ methods) were added to 2×10
4
 recipient
cells grown in chamber slides (IBIDI, Martinried, Germany). After 
2–3 h of incubation, cells were fixed in 4 % w/v paraformaldehyde 
(Sigma–Aldrich, Milan, Italy) for 10 min. Next, cells were stained by 
Alexa Fluor 647 conjugate phalloidin (Immunological Sciences, 
Rome, Italy) and nuclei by Hoechst 333258 dye (Sigma–Aldrich, St 
Louis, MO, USA). Exosomal and cellular staining were analyzed by 
Olympus FV-1000 laser-scanning confocal microscopy. 
5.7 Quantification of exosomes and cells associated fluorescence. 
The quantification of EXOs was performed according to 
Sargiacomo’s procedure (Coscia C., 2016). EXO-C16 and  
fluorescent beads ranging in size from 0.1 to 1.0 μm and background 
noise were analyzed for fluorescence and size. Two thousand of 
Flow-Count Fluorospheres were used to determine EXOs number. To 
quantify the exact number of exosome transmission, we used a 
Quantum™ MESF (Molecules  of  Equivalent  Soluble 
Fluorochrome) calibration kit to convert fluorescence in a quantum 
per exosome  traceable by FACS. To determine MESF per EXOs and 
cells, we transformed fluorescence data (arithmetic mean) of EXOs 
using the QuickCal analysis template provided with each Quantum™ 
MESF lot (Bang Laboratoires, Inc).  See fig. 29. 
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Figure 29 
Figure 29. In vitro quantification of Fluo-EXOs. 
5.8 In vitro experimental model of fusion.  
EXOs, recovered from conditioned media either of melanoma or 
EWS cells, were incubated with respective recipient cells for 30 min 
at 37 °C before performing expression studies and functional assays. 
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Vesicle preparations were used immediately after isolation. The same 
amounts of control and treated EXOs were utilized. 
5.9 Functional assays. 
Migration was assayed, as previously described, using uncoated cell 
culture inserts (Corning Costar Corporation, Cambridge, MA) with 
8μm pores. Five x 104 cells were plated in the upper compartment in
100 µL of DMEM without serum, while 600 uL of DMEM and 10% 
FBS-UC were added in the lower compartment. For invasion studies, 
the insert membrane was coated with 100 g/cm
2
 of Matrigel (Becton
Dickinson, Bedford, MA) and 10
5
 cells plated in the upper
compartment. Both assays were incubated at 37°C in 5 % CO2. After 
24 or 48h , the cell remained in the upper surface of the membrane 
were removed , while those attached to the lower surface were fixed 
and stained with Crystal Violet. After solubilization, cell 
migration/invasion were quantified by spectrophotometric analysis 
with an ELISA plate reader at a wave length of 595 nm. 
For tube formation assays, melanoma cells fused with EXOs were 
seeded into culture slide wells coated with 100 mg/cm
2
of Matrigel
growth factor reduced (Becton– Dickinson, Bedford, MA,). Tube-
like formations defined as ≥2 cells forming elongated structures were 
counted after 24–48 h of incubation by microscope (JULI 
microscopy, Twin Helix, MI, Italy) at 10 × magnification from four 
different fields for each condition. Tube formation was analyzed 
manually and by the Image J software. Experiments were conducted 
at least three times. 
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5.10 Cell cycle analysis. 
Cell cycle analysis was performed in synchronized or not 
synchronized melanoma cells. In the first case cells were 
synchronized by the addition of Hydroxyurea (HU), final 
concentration 2 mM, per 16 h. Cultures were then washed and 
medium replaced. From this point, considered as t= 0, cells were 
monitored while they proceed along the cell cycle after specific 
treatments (i.e., EXO internalization or BKM120 supplementation). 
In not synchronized experiments, cells were seeded at roughly 60–70 
% confluence and treated in DMEM supplemented with 5 % FBS in 
triplicate. Cells were collected, washed in PBS, and suspended in 
propidium iodide (PI) staining buffer (PBS containing 1 % Triton X-
100, 50 mg/ml PI and50 mg/ml RNase). Cells were then incubated 
for 30 min (37 °C) and DNA content measured by flow cytometry 
using a BD FACS Canto cytometer (BD Biosciences,CA). 
5.11 Immunofluorescence analysis. 
Immunofluorescence was performed on adherent cells grown on 
coverslips for 72 h and fixed in 4% paraformaldehyde or in 
methanol/acetone 3:7, and permeabilized with 0.15% Triton X-100 
in phosphate-buffered saline, and incubated with the following 
antibodies: anti-β-III Tubulin 1:50 (Sigma-Aldrich St Louis, MO), 
anti-NF-H 1:50 (Cell Signaling Technology); anti-Phalloidin 
(Immunological Sciences, Rome, Italy). 
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Nuclei were counterstained by bisbenzimide Hoechst 33258 (Sigma-
Aldrich). Cell fluorescence was then evaluated by microscope Nikon 
Eclipse 90i (Nikon Instruments, FI, Italy). 
EXO-induced differentiation was evaluated by immunofluorescence 
after 3 days of culture in low serum condition. 
5.12 Immunoblot analysis.  
Western blot analysis was performed according to standard 
procedure. EXOs samples were lysed in buffer (0.5 % Triton; 300 
mM NaCl; 50 mM TrisNaCl). Cells were lysed in a cold lysis buffer 
containing 1 % NP40, 200 mM NaCl, 50 mm Tris pH 7.4. A protease 
inhibitor cocktail 20X(Sigma–Aldrich, St Louis, MO, USA) was 
always included. Protein concentration was measured by the Biorad 
protein assay (Hercules, CA,).Cell lysates and EXOs were separated 
by the precast NuPAGE polyacrylamide gel system 
(LifeTechnologies). Proteins are transferred to a nitrocellulose 
membrane (Amersham, HybondC).The membranes were blocked 
with 5% non fat dry milk in TBST 0.05% Tween and incubated with 
specific antibodies. 
Antibodies listed below were used in accordance to the 
manufacturer’s instructions: CD63 (SBI System Biosciences, 
Mountain View, CA), RAB5B, TSG101, HSP90 , CD99, NOTCH1 
and NOTCH3 and CycD1 (Santa Cruz Biotechnology Dallas, TX), 
LAMP2 and CAV-1 (BD Biosciences, CA), RAB27A (Abnova, 
Taipei City, Taiwan), p85β (Abcam, Cambridge, MA), AKT, ph-
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AKTSer473 and p27Kip1 (Cell Signaling, Beverly, MA). β-ACTIN 
(Oncogene Research, La Jolla, CA) and α-TUBULIN (Sigma-
Aldrich) were used as a loading control and subsequent 
quantification. Anti-rabbit or anti-mouse antibodies conjugated to 
horseradish peroxidase (GE Healthcare; cat. NA934V and NA931V) 
were used as secondary antibodies. The expression levels were 
evaluated by the AlphaView (Protein-simple, CA) or Image Quant 
Software (Uppsala, Sweden). 
5.13 Luciferase assay 
A total of 2x10
4
 cells/well was plated in triplicate and grown for 24 h
before transfection in a 24-well plate coated with 3 μg/cm2
fibronectin (Sigma-Aldrich). Cells were transfected with 200 ng of 
the appropriate responsive reporter pRL-TK (Promega, Madison, WI, 
USA) by Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol. After 24 h, the same amounts of control 
(CTR) or CD99-null purified EXOs were incubated with recipient 
cells for 30 min at 37 °C before performing luciferase assay. Firefly 
luciferase activity was normalized to that of Renilla luciferase 
included as internal control. Luciferase activity was measured by the 
Dual-Glo Luciferase Assay System (Promega) according to the 
manufacturer’s protocol.  
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5.14 RNA preparation and qRT‑PCR. 
RNA was isolated from cell lines and EXOs using the “Total RNA 
Purification micro Kit” (NorgenBioteK Corp, Canada) according to 
the manufacturer’s protocol. In the first setting of experiment, to 
avoid any possible contamination of external RNAs, isolated EXOs 
were pre-treated with RNase (Roche, Nutley, NJ) for 10 min at 37 
°C, before RNA extraction. Total RNA concentration was 
quantitated by spectrophotometry and the quality was assessed by 
measuring the optical density ratio at 260/280 nm. In case of very 
low amounts, RNA quality was assessed by Nanodrop. RNA samples 
were stored at -80°C. After denaturation at 65°C for 10 minutes, 
RNAs was reverse transcribed and qRT-PCR performed by the 
TaqManTechnology, using the ABI PRISM 7700 DNA Sequence 
Detection System (Life Technologies). 
Real time quantification (qRT-PCR) of miR-222 (#000525), miR-
34a (#000426) p27Kip1 (#Hs00153277_m1), FGF2 
(#Hs00266645_m1), VEGFA (#Hs000900055_m1), ITGβ3 
(#Hs00173978_m1) and Bcl-2 (#Hs00153350_m1) were performed 
according to the TaqMan technology (Applied Biosystems, Foster 
City, CA). MiR-16 (#000391), RNU6B (#001093) and GAPDH 
(4326317E) were used as internal controls. 
For gene profiling study in EXOs, total RNA was reverse transcribed 
and RT products analyzed for gene expression using TaqMan Array 
Plate for Human Tumor Metastasis genes(Applied Biosystems, 
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Foster City, CA) containing a total of 95 unique assays specific to 
human genes and one manufacturing control (18S). 
5.15 Statistical analysis. 
Differences were statistically evaluated using Student’s t test. p < 
0.05 was defined as statistically significant. ANOVA analysis was 
performed using GraphPad version 4.0 for Windows (GraphPad 
Software, San Diego, CA) followed by Student–Newman–Keuls post 
hoc test when appropriate. 
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